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This second annual report o f  the N ational C enter for H IV /A ID S, Viral H epatitis, STD  and TB prevention highlights 
some o f the m ajor achievements and 
challenges faced by our organiza­
tion in 2008, and looks forward to 
the opportunities for even better 
prevention in the year ahead. This 
report is part o f  the fulfillment o f  our 
C enter’s com m itm ent to ensure that 
we are accountable and transparent in 
our work to protect health, prevent 
disease, and use the funds that are 
entrusted to us w ith the greatest care. 
We are com m itted to the ideals o f  the 
new adm inistration to ensure we earn 
your trust and work w ith in  an open 
environm ent in which we ask for your 
participation and collaboration. This 
active accountability and engagement 
will certainly strengthen and prom ote
efficiency and effectiveness in the 
w ork we do to protect your health.
You will find in this report, briefs on 
the im pact the work o f  this C enter 
and our partners has on the lives and 
well-being o f  people at hom e and 
abroad. The title, “M oving Forward 
W ith  Prevention,” was chosen to 
emphasize the incredible change and 
hope for m aking concrete advances 
in prevention from the past year. O u r 
stories show how  we have continued 
to strengthen our science by grow­
ing the size o f  our research efforts, 
strengthening our research partner­
ships and collaborations, and develop­
ing and m entoring new researchers 
in the prevention arena. We have 
continued to deliver life-saving, effec­
tive, evidence-based prevention pro­
grams at hom e and abroad. A nd we 
remained focused on reaching more 
people in more places w ith life-saving 
prevention interventions. W e achieved 
this by increasing the reach o f H IV  
testing and other prevention interven­
tions for African Americans through 
the H eighten N ational Response 
initiative; by increasing the purchase 
and delivery o f  Hepatitis B vaccines 
in our A dult Vaccine Initiative; and 
through the dram atic scale-up o f  H IV  
treatm ent and the expansion o f  inter­
national prevention and care efforts 
under the President’s Emergency Plan 
for AIDS Relief (PEPFAR).
The epidemics o f  H IV  and other 
STDs, hepatitis, and TB in the U nit­
ed States and overseas are large and 
complex, but we have made progress 
over the last year both in the United 
States and throughout the world. In 
the U nited States:
• New diagnoses and rates o f 
TB continued to fall and, 
in 2008, were at the low­
est levels ever recorded.
• N ew  estimates o f  H IV  incidence, 
attained through the use o f  break­
through technology, show that 
incidence has rem ained mostly 
stable since the late 1990s.
• Expansion o f  hepatitis B vac­
cination programs have brought 
continued declines in acute 
hepatitis B infections.
• Advances in tracking o f  hepa­
titis C  infection continue.
• N ew  efforts have been started that 
focus on mobilizing com m uni­
ties to reduce HIV, STD , TB and 
hepatitis health disparities and 
prom ote greater health equity.
• Large investments have been made 
to prom ote H IV  testing, especially 
in areas w ith high rates o f  disease 
am ong African Americans.
• The planning and delivery o f 
our prevention investments and 
programs are being improved 
by providing new program  and 
funding opportun ity  announce­
m ents that are more balanced 
between national and local pre­
vention priorities and needs.
• N ew  prevention programs have 
been introduced and established 
programs and approaches re­
fined, including programs that 
are collaborative and integrate 
services for more than one disease 
or risk; that begin to address the
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social determ inants o f  health; 
and that pu t the funding in ar­
eas where there is evidence that 
our work is improving health.
• N ew  com m unication technolo­
gies are being used to prom ote 
H IV  and STD  prevention.
This year’s report also highlights the 
staff o f  N C H H S T P  O u r C enter 
attracts an exceptionally diverse set 
o f  public health and support profes­
sionals w ith a range o f  skills and 
experience that is perfect for the de­
velopm ent and delivery o f  evidence- 
based and high-im pact prevention 
programs, research and policies. We 
are especially proud of, and thank­
ful for, the work o f  the more than 
1,300 locally employed staff who are 
citizens or residents o f  the countries 
that host C D C  programs. These staff 
provide essential program  and support 
functions. O u r expert staff com bined 
w ith our unique relationships w ith 
governmental, non-governm ental 
and private sector partners, form  our 
foundation that provides us the op­
portun ity  to cham pion public health 
and accelerate our disease prevention 
and health protection activities.
As we move toward the next decade, 
we m ust continue to be open to 
change to ensure we continue to 
achieve excellence in our prevention 
efforts. O u r upcom ing strategic plan 
will set out our vision for the Center,
reflecting w hat we’ve heard from  our 
staff, partners and the public. We will 
strengthen our focus on health and 
health protection and not simply on 
the prevention o f  disease. We will 
move away from a one-size-fits-all 
prevention service to one that is tai­
lored to the needs o f  our partners and 
the people we serve, m aintaining our 
focus on quality, effectiveness and im ­
pact, while ensuring equitable access.
W e are com m itted to building on the 
achievements, infrastructures and net­
works for prevention that have existed 
since the creation o f  our C enter more 
than a decade ago. We will continue 
to build an organization that is effec­
tive in protecting the health o f  the 
public at hom e and abroad by:
• H elping to reduce the incidence 
and burden o f  H IV  and other 
STDs, hepatitis and TB;
• Im proving our efforts to 
protect and m aintain health 
and health equity;
• Ensuring that all that we 
do is based on sound evi­
dence o f effectiveness;
• Ensuring that our research invest­
m ents continue to contribute 
directly to health improve­
m ent and health protection;
• Ensuring that people have 
the inform ation they need to
protect themselves, their loved 
ones and their communities;
• Building strong, transparent 
and collaborative partnerships 
to improve our collective ca­
pacity to respond to ongoing 
and emerging challenges;
• Providing clear, accurate and useful 
health protection advice and guid­
ance that is the first choice for the 
public, health professionals, other 
key stakeholders, and the media;
• Ensuring the m ost effective use o f 
resources in our programs to maxi­
mize health im pact and in so doing 
continue to attract the brightest 
and best w orking in all parts o f 
the public health protection field.
We will work to meet the standards 
set by this new adm inistration that 
governm ent should be transparent 
and accountable; participatory and 
com m itted to public engagement; and 
collaboration. We rem ain com m itted 
to C D C ’s core values o f  respect, integ­
rity and accountability and our goal 
to ensure that high-quality prevention 
services are available to those in need. 
We are com m itted to ensuring that 
our partners and the public get the 
right inform ation, at the right time 
and in the right way, and that our 
science prom otes the delivery and 
im plem entation o f  the m ost effective 
programs at hom e and around the 
world.
Kevin A. Fenton, M .D ., Ph.D ., F.F.P.H. 
Director, N ational C enter for H IV /A ID S, 
Viral Hepatitis, STD , and TB Prevention
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History
T he National Center for HIV/AIDS, Viral Hepati­tis, STD, and TB Preven­
tion (NCHHSTP) is part of the 
Centers for Disease Control and 
Prevention (CDC), an agency of 
the U.S. Department of Health 
and Human Services (HHS). It 
is one of four national centers 
housed within CDC’s Coordinat­
ing Center for Infectious Diseases 
(CCID).
The National Center for HIV/ 
AIDS, STD, and TB Prevention 
(NCHSTP) was established in 
1994 to bring together most of 
CDC’s HIV prevention activities 
under a single organizational home 
that also includes sexually trans­
mitted disease (STD) prevention 
and tuberculosis (TB) elimination 
programs. In 2000, the Global 
AIDS Program (GAP) was added 
to NCHSTP in response to the 
global HIV/AIDS epidemic. In 
2006, CDC’s Division of Viral 
Hepatitis was added and the 
center was renamed the National 
Center for HIV/AIDS, Viral Hep­
atitis, STD, and TB Prevention 
(NCHHSTP).
The diseases addressed by N C H H ­
STP share a number of com­
monalities. They have similar or 
overlapping at-risk populations— 
including racial and ethnic minor­
ities, men who have sex with men, 
and injection drug users. These 
diseases also have important in­
teractions. Those who are infected 
with certain STDs, such as syphilis 
or gonorrhea, are at greater risk 
for HIV infection. Likewise, those 
who are infected with HIV are 
far more susceptible to TB disease 
because their immune systems 
are weakened. Similarly, approxi­
mately 33% of those infected with 
HIV are co-infected with hepatitis 
C and 10% are co-infected with 
hepatitis B.
These diseases also share similar 
social determinants, including 
poor access to health care, stigma, 
discrimination, homophobia, and 
poverty. In the area of prevention 
and control, effective, science- 
based interventions exist to reduce 
the burden of TB, viral hepatitis, 
most STDs, and HIV.
Mission
NCHHSTP maximizes public 
health and safety nationally and 
internationally through the elimi­
nation, prevention, and control 
of disease, disability, and death 
caused by HIV/AIDS, viral hepati­
tis, other STDs, and TB.
NCHHSTP achieves its mission
by:
• Developing, implement­
ing, and evaluating effective 
science-based prevention 
programs for HIV, viral 
hepatitis, STDs, and TB.
• Developing high quality 
research and translating rel­
evant findings into preven­
tion policy and programs.
• Creating and strengthening 
strategic relationships and 
networks with individu­
als and organizations.
• Strengthening and promot­
ing surveillance activities 
and findings for program 
planning, public health re­
sponse, and evaluation.
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W h o  Are We?
As a leader in preventing and 
controlling HIV infection, 
viral hepatitis, STDs, and 
TB, NCHHSTP applies well- 
integrated, multidisciplinary 
programs of research, surveillance, 
risk factor and disease 
intervention, and evaluation.
NCHHSTP addresses domestic 
HIV/AIDS prevention through 
an array of public health activities 
including monitoring the disease’s 
impact, facilitating and support­
ing partnerships, implementing 
prevention programs, conducting 
intervention research and program 
evaluation, delivering techni­
cal assistance to build the 
capacity of organizations to 
offer prevention services, and 
developing policy and com­
munications to support HIV 
prevention. These activities 
are conducted with a wide 
range of public- and private- 
sector partners, including 
state and local health depart­
ments, community-based 















ucate health care 
and public health professionals to 
improve identification of persons 
at risk for chronic hepatitis C 
infection and ensure appropriate 
counseling, diagnosis, manage­
ment, and treatment. NCHHSTP 
also conducts research and policy 
development to control hepatitis 
A, B, and C and supports surveil­
lance to monitor who is getting 
chronically infected with viral 
hepatitis and to ensure appropriate 
counseling, testing, and medical 
management of infected persons.
To prevent STDs, NCHHSTP 
provides national leadership 
through research, surveillance, 
policy development, and assistance
to states, territories, and local 
health departments. NCHHSTP 
also provides federal support for a 
community-wide, science-based, 
interdisciplinary systems approach 
to STD prevention and conducts 
prevention research to improve 
methods and delivery of preven­
tion services and to develop and 
refine interventions. The center’s 
focus areas include preventing 
STD-related infertility in women, 
preventing adverse outcomes of 
pregnancy, eliminating syphilis, 
preventing cancer related to sexu­
ally transmitted infections (STI), 
and preventing STI-related HIV 
transmission, reducing STI-related 
health disparities, addressing the 
effects of the social and economic 
determinants and the costs of 
specific STDs among specific 
populations, and strengthening 
STD prevention capacity and in­
frastructure.
NCHHSTP provides leadership 
and assistance to domestic and in­
ternational efforts to prevent, con­
trol, and eliminate TB. NCHH- 
STP provides grants to states and 
other entities for prevention and 
control services, researches the pre­
vention and control of TB, funds 
demonstration projects, and 
sponsors public information 
and education programs. In 
addition, the center supports 
education, training, and clini­
cal skills improvement activi­
ties to prevent, control, and 
eliminate TB. NCHHSTP 
also manages the national TB 
surveillance system and pro­
vides laboratory support for 
TB control activities. Because 
more than half of the U.S.
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TB cases are among those born 
outside of the United States, one 
of the TB program’s chief aims is 
to prevent and control TB among 
foreign-born persons.
NCHHSTP also includes the 
Global AIDS Program (GAP), 
which was initiated in 2000 to ad­
dress the international HIV/AIDS
I
 epidemic by assisting resource- 
constrained countries. GAP assists 
such countries in preventing HIV 
infection, improving treatment, 
care and support for people liv­
ing with HIV, and building vital 
capacity and infrastructure to 
address the global HIV/AIDS 
epidemic. GAP’s highly trained 
physicians, epidemiologists, 
public health advisors, behavioral 
scientists, and laboratory scien­
tists support the national HIV/ 
AIDS strategies of more than 60 
countries in Africa, Asia, Central 
and South America, and the Ca­
ribbean through its country and 
regional offices. In 2003, when 
the President’s Emergency Plan 
for AIDS Relief (PEPFAR) was 
announced, GAP joined this uni­
fied U.S. Government response to 
global HIV/AIDS. In 2008, Con­
gress extended PEPFAR for five 
more years with the passage of the 
PEPFAR reauthorization bill. The 
legislation authorizes $48 billion 
to the program through 2013.
W h e r e  Are We?
NCHHSTP employs a cadre of 
dedicated staff to accomplish its 
domestic and international objec­
tives. The center has more than
3,500 staff comprised of federal 
employees, fellows, contractors, 
and special overseas staff. O f 
these, approximately 1,700 work 
in NCHHSTP’s offices in Atlanta, 
Georgia. In addition, 300 staff are 
assigned to field offices in 29 states 
and the District of Columbia. 
NCHHSTP also employs approxi­
mately 1,500 federal employees, 
contractors, fellows, and locally 
employed staff working in interna­
tional field offices in more than 30 
countries.
NCHHSTP Key 
Prior i t ies
NCHHSTP has three key priori­
ties that are guiding center-wide 
initiatives and focusing work 
group activities in 2008:
• Reducing health disparities
• Encouraging program collabo­
ration and service integration
• Maximizing global synergies
These priorities guide NCHH- 
STP’s overall mission and pro­
grams. NCHHSTP has established 
eight internal workgroups to ad­
dress these three key programmatic 
priorities. These workgroups are 
focusing on topics such as health 
issues in corrections facilities, 
surveillance and strategic informa­
tion, and use of modeling and 
health outcome measures as tools 
to aid prevention efforts.
For example, the surveillance and 
strategic information workgroup 
published the 2006 Disease Pro­
file report (http://www.cdc.gov/
nchhstp/Publications/). The report 
brings together annual NCHH- 
STP surveillance data, reported by 
division, and is the first in a series 
of planned annual profiles. When 
the data are compared across 
divisions, they show that certain 
populations are particularly vul­
nerable to the overlapping occur­
rence of these diseases. This first 
issue includes a special focus on 
African-American men to illustrate 
how these diseases may interact 
and the associated set of histori­
cal, structural, and sociocultural 
factors that influence disease rates 
and contribute to excess disease 
burden.
R ed u c in g  H e a l t h  
D is p a r i t ie s
NCHHSTP strives to improve 
the health of populations dispro­
portionately affected by HIV, viral 
hepatitis, STDs and TB, and re­
lated diseases and conditions, with 
the ultimate goal of eliminating 
health disparities. One of CDC’s 
overarching health protection 
goals is to give priority to activities 
that have the greatest health im­
pact and reduce health disparities. 
The Office of Health Disparities 
(OHD) leads this effort within the 
center.
A health disparity is the difference 
that separates a group of interest 
from a reference group on an indi­
cator of health that is measured in 
terms of rate, proportion, mean, or 
some other quantitative measure. 
Differences may occur by gender, 
race or ethnicity, education, in­
come, disability, geographic loca-
6  N a t i o n a l  C e n t e r  f o r  H I V / A I D S ,  V i r a l  H e p a t i t i s ,  S T D ,  a n d  T B  P r e v e n t i o n
AB OUT  NCHHSTP
tion, or sexual orientation. Social 
determinants of health such as 
poverty, unequal access to health 
care, lack of education, stigma, 
and racism are closely connected 
to health disparities.
OHD coordinates and tracks 
health disparity activities within 
the center and provides leadership 
in support of research, surveil­
lance, education, training, and 
program development to reduce 
health disparities. OHD works 
with NCHHSTP leadership to 
promote a diverse public health 
workforce through internships, 
fellowships, training programs, 
and other mentoring activities 
for emerging scientists and public 
health professionals. OHD also 
coordinates and contributes to 
HHS reports regarding center ac­
tivities for racial/ethnic minorities.
Major accomplishments and ac­
tivities in 2008 aimed at reducing 
health disparities include the fol­
lowing.
H i s p a n i c /L a t in o  
Consul ta t ion
O f the more than 1 million 
Americans living with HIV/AIDS, 
17.5% are Hispanic or Latino.
In April 2008, NCHHSTP 
held a consultation on HIV/
AIDS prevention for Hispanic/ 
Latino communities. More than 
100 leaders of Hispanic-serving 
organizations joined academic 
researchers, policy makers, 
public health practitioners, and 
government agency representatives 
to formulate comprehensive and 
effective strategies for preventing 
HIV infection among Hispanics 
and to develop a National Plan 
of Action. The goals of the 
consultation included identifying 
ways that CDC and Hispanic 
leaders can work together to 
implement HIV prevention 
activities, developing a shared 
vision for reducing new HIV 
infections among Hispanics, and 
increasing access to culturally 
appropriate prevention, care, and 
treatment services for the Hispanic 
community.
The recommendations NCHH- 
STP received from consultation 
attendees highlighted the need for 
provision of culturally competent 
services, development of structural 
approaches to HIV prevention, 
improved surveillance of Hispan- 
ics/Latinos, better collaboration 
with Hispanic/Latino leaders and 
other nations, and more training 
opportunities for community lead­
ers and service providers. Consul­
tation participants outlined a bold 
agenda that CDC will carefully 
consider as it develops a national 
action plan to address HIV/AIDS 
among Latinos.
In response to consultation rec­
ommendations, NCHHSTP has 
named an acting Associate Direc­
tor for the Hispanic Latino Execu­
tive Committee. It has also formed 
an internal Hispanic Latino Ex­
ecutive Committee within the Di­
vision of HIV/AIDS Prevention.
D i s s e m in a t io n  o f  
H e a l t h  D ispar i t ies  
Research
In collaboration with guest 
editors at NCHHSTP, the 
peer reviewed journal Women 
and Health published a 
special issue entitled Black 
Women and HIV/AIDS: Epi­
demiology, Risk Behaviors, and 
Prevention [Volume 46 (2/3)]. 
The special issue includes 
papers on HIV/AIDS surveil­
lance, best practices for im­
proving health education, 
selection of evidence-based 
behavioral interventions, and 
other HIV prevention strate­
gies for black women.
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I n a u g u r a l  Session o f  
the NCHHSTP S u m m e r  
Fel lows Forum
The NCHHSTP Summer Fellows 
Forum is an eight-week seminar 
series designed to provide summer 
fellows participating in racial and 
ethnic minority training programs 
with knowledge and skills in 
conducting public health preven­
tion, intervention, surveillance or 
epidemiologic research in HIV/ 
AIDS, viral hepatitis, STD, and 
TB. The forum, which was initi­
ated in Fiscal Year (FY) 2008, also 
fosters skills in communicating 
research findings through seminar 
presentations.
Undergraduate and graduate fel­
lows are matched with NCHH- 
STP mentors who guide them 
through the research process and 
introduce them to a broad array 
of NCHHSTP programs and re­
search. Fellows are also able to at­
tend division and CDC-wide sem­
inars offered during the summer. 
FY 2008 summer fellows with 
mentors on research topics such as 
“Expanding the Guidelines for Dis­
continuation o f Airborne Infection 
Isolation Precautions for Patients 
with Multidrug-resistant Tuberculo­
sis, ” “Assessing Evaluation Capacity 
o f Community Based Organizations 
Implementing H IV  Programs, ” 
and “Health Information-seeking 
Behaviors o f Spanish-speaking His- 
panics.” The NCHHSTP Summer 
Fellows Forum is a component of 
the NCHHSTP Deputy Direc­
tor’s Initiative on PublicHealth 
Workforce and Leadership Devel­
opment.
H e a l th  D ispar i t ies  
Work Group
In August 2008, the Health Dis­
parities Work Group, in partner­
ship with the CDC Sexual and 
Gender Minorities Workgroup, 
participated in the 2008 Black 
Gay Pride event by organizing 
three health discussion groups at 
the annual event in Atlanta. The 
discussion groups addressed health 
disparities challenges for:
• Gay or bisexual men
• Lesbian or bisexual women
• Transgender persons
E n c o u r a g in g  
P r o g ra m  
C o l l a b o r a t i o n  and  
Serv ice  I n t e g r a t i o n
Program collaboration and ser­
vice integration (PCSI) is one 
of NCHHSTP’s three strategic 
programmatic priorities. The focus 
of PCSI is to promote integrated
service delivery at the client level 
or point of service delivery; it 
does not address integration at 
the organizational or structural 
level. CDC’s vision for PCSI is to 
provide prevention services that 
are comprehensive, science-based, 
and high quality to appropriate 
populations at every interaction 
with the health system.
PCSI activities in 2008 focused on 
formalizing center- and division- 
level action plans and policy 
statements based on the results 
of the external consultation held 
in August 2007, communicating 
these plans to external partners, 
and making progress toward goals 
and objectives.
G r e e n / W h i t e  Pa p er
In 2008, NCHHSTP revised a 
green paper on PCSI to produce 
a PCSI white paper, based on dis­
cussions with internal and external 
stakeholders. The white paper 
articulates NCHHSTP’s strategic 
plan for PCSI through 2011. The
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document describes a framework 
for conceptualizing PCSI, identi­
fies how CDC will work with 
internal and external stakeholders 
to accomplish relevant goals, out­
lines key measures to monitor and 
evaluate progress, and describes 
how NCHHSTP will work with 
partners at national, state, and lo­
cal levels to advance this strategic 
priority. The primary audience 
of this document is domestic 
NCHHSTP-funded programs.
The PCSI white paper is to be 
published in FY 2009.
Act ion Plan a nd  
E v a lu a t i o n
To track activities, NCHHSTP 
developed an action plan for pro­
gram collaboration and service in­
tegration for FY 2008. The action 
plan tracks activities and monitors 
progress toward PCSI goals and 
objectives. NCHHSTP is also 
finalizing an evaluation design for 
monitoring progress toward PCSI 
implementation in the field for FY 
2009.
C o m m u n ic a t i o n  a nd  
S h a re d  Leadership
NCHHSTP launched a web 
portal on PCSI at http:// 
www.cdc.gov/nchhstp/ 
programintegration/Default. 
htm in FY 2008. The web portal 
is a resource for all relevant 
NCHHSTP publications and 
other products related to PCSI.
Pr og ra m  a n d  Pol icy  
I m p r o v e m e n ts
NCHHSTP has made progress 
on addressing some of the prior­
ity areas and activities for PCSI 
identified in the center’s external 
consultation on PCSI, held in Au­
gust 2007. Key priorities identified 
were integrated funding, integrat­
ed training, and integrated surveil­
lance. Achievements in these areas 
include the following:
• NCHHSTP’s director and staff 
conducted a joint site visit to 
the Southwest to learn about 
specific issues and needs among 
rural Native American tribal 
nations. One major result of 
this visit is strengthened lan­
guage in all NCHHSTP fund­
ing announcements related to 
tribal government eligibility.
• Standard operating procedures 
for developing funding op­
portunity announcements 
were changed so that all new 
announcements are reviewed 
early in development to iden­
tify integration opportunities 
and ensure adequate time for 
cross-division review. In 2008,
PCSI language and activi­
ties were added to four major 
funding announcements.
Training
As a significant first step toward 
enhancing training on PCSI, 
NCHHSTP held a meeting 
with its funded training entities 
on June 24, 2008 in Long 
Beach, California. The purpose 
of the meeting was to develop 
a shared vision on integrated 
training opportunities within 
NCHHSTP-funded training 
entities and to identify priority 
activities to facilitate integrated 
training. The meeting report is 




Surve i l l ance
A low-cost, high-impact activity 
identified by the external PCSI 
consultants was to develop com­
mon assurance of confidentiality 
statements for HIV/AIDS, viral 
hepatitis, STDs, and TB to facili­
tate sharing of surveillance data 
across and within program areas. 
NCHHSTP is pilot testing several 
models of assurances of confiden­
tiality obtained from states.
M a x i m i z i n g  G lo ba l  
Synerg ies
In 2008, NCHHSTP saw the 
continued expansion of the Global 
AIDS Program (GAP) and the 
mobilization of activities address­
ing drug-resistant TB. In today’s 
world, success in prevention
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requires interdependent relation­
ships that are global in nature.
NCHHSTP is working to maxi­
mize global synergies by fostering 
interdependent programmatic re­
lationships related to international 
activities between NCHHSTP
divisions. The goal is to ensure 
active collaboration between 
NCHHSTP divisions to leverage 
NCHHSTP, CCID, and CDC 
resources and to maximize health 
impact. NCHHSTP actively 
pursues and seeks input about in­
ternational program development 
and public health research, fosters 
robust internal and external part­
nerships, and commits to novel 
and participatory approaches for 
implementation and dissemina­
tion. Following are some activities 
that support this priority.
S t r e n g t h e n i n g  
L a b o r a t o r y  Systems  
G lo b a l l y
Playing a key leadership role, GAP 
helped lead a January 22-24, 2008 
meeting that brought together a 
total of 120 experts and policy 
makers from 33 countries, includ­
ing representatives from Cambo­
dia, Haiti, India, Thailand, Viet­
nam and 28 Sub-Saharan African
countries, to address strengthening 
national laboratory systems in 
order to deliver quality services for 
universal access to HIV/AIDS, TB 
and malaria prevention, care and 
treatment services.
On January 24, these leaders 
signed the Maputo Declaration 
on Strengthening of Laboratory 
Systems. This declaration calls 
on national governments to give 
priority to laboratory systems by 
developing a national laboratory 
policy within their national health 
development plans. It calls for na­
tional governments to establish a 
department of laboratory systems 
within the Ministry of Health and 
to work with partners to develop 
national strategic laboratory plans 
that integrate laboratory support 
for the major diseases of public 
health importance, including HIV, 
TB, and malaria.
GAP is supporting multiple coun­
tries across Africa in developing 
these national strategic laboratory 
plans. Training, logistics and com­
modities management, facility 
and equipment maintenance, and 
quality assurance are cross-cutting 
aspects of all disease-specific labo­
ratories, and GAP is providing
support to address all of these by 
helping countries develop national 
strategic laboratory plans. These 
plans will reduce parallel disease- 
specific lab systems, building ef­
ficiency and augmenting countries 
ability to respond effectively to 
numerous diseases including HIV, 
TB, malaria, and avian influenza.
Leadership a n d  
M a n a g e m e n t  Training  
for  Local ly  Emplo ye d  
S t a f f
As part of its commitment to 
continuing employee education, 
CDC offers extensive management 
and leadership training through its 
nine-month Leadership Manage­
ment Institute. The 2007-2008 
academic year marked the first 
time that the Leadership Man­
agement Institute courses have 
been available to CDC’s locally 
employed staff (LES) in overseas 
field locations. These are employ­
ees who are citizens or residents of 
the countries that host CDC pro­
grams and who provide essential 
program and support functions. 
CDC’s global presence has grown 
exponentially over the past decade 
and the number of LES has risen 
just as dramatically. There are 
now approximately 1,300 GAP 
LES. About 600 are in middle- to 
senior-level positions, including 
medical officers, epidemiologists, 
and laboratorians.
Recognizing the pivotal role of 
LES in achieving the CDC’s goal 
of implementing sustainable global 
programs, GAP, with the support 
of the CDC Coordinating Office 
for Global Health, nominated six
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GAP LES to attend CDC’s Lead­
ership Management Institute. The 
six nominees are leaders in their 
respective fields from Nigeria, 
South Africa, Uganda, and Zam­
bia.
For their Leadership Management 
Institute project, the four doctors 
and two public health profession­
als developed recommendations 
to CDC on how to better support 
LES and the global health work­
force in general. These recommen­
dations were presented in their 
report, “Strengthening CDC’s In­
ternational Operations: Optimizing 
the Role o f CDC Locally Employed 
Staff,” which was issued in Au­
gust 2008. They proposed several 
overarching recommendations on 
career path and development, clas­
sification and compensation, and 
organization design that will help 
lay the groundwork for developing 
a sustainable global public health 
workforce.
During visits to Washington,
D.C., in March and August 2008, 
the six leaders became ambassadors 
for global health workforce issues, 
presenting to staff at the White 
House Office of Science and Tech­
nology, Office of the First Lady, 
Faith-Based and Community Ini­
tiatives, and the National Security 
Council. They also met with poli­
cy makers and leaders from CDC, 
HHS, and the Office of the Global 
AIDS Coordinator and were pre­
senters at a Center for Strategic 
and International Studies panel, 
where they discussed local work­
force development. (This presenta­
tion was webcasted by the Kaiser 




NCHHSTP works in col­
laboration with governmental 
and nongovernmental partners 
at community, state, national, 
and international levels. NCHH- 
STP funds prevention efforts, 
demonstration projects, capacity 
building efforts, and surveillance 
activities in state, local, and ter­
ritorial health departments, as well 
as community-based and national 
organizations.
NCHHSTP coordinates its ef­
forts with other federal agencies, 
including several other agencies 
within HHS. For example, the 
Health Resources and Services 
Administration (HRSA) is autho­
rized under the Ryan White HIV/ 
AIDS Treatment Modernization 
Act to support treatment programs 
for people living with HIV and 
AIDS, and HRSA utilizes data
from NCHHSTP’s HIV/AIDS 
surveillance systems to guide fund­
ing for these programs. These data 
are also used to guide funding for 
the Department of Housing and 
Urban Development’s Housing 
Opportunities for People with 
AIDS program.
NCHHSTP also reaches out to 
partners in business, media, com­
munities, and other groups. For 
example, in FY 2008, in an effort 
to support partner mobilization 
activities and facilitate communi­
cation with its many partners in 
the Heightened National Response 
to the HIV/AIDS Crisis among 
African Americans initiative, 
NCHHSTP has launched the 
HNR Community Web Server. 
The Community Web Server is 
an online community designed 
to help HNR partners make 
connections, access information, 
share best practices, discuss and 
solve challenges, and seek answers 
related to HIV prevention among 
African Americans. The Web site 
address is https://www.cdcnpin. 
org/communities/hnr/.



















AB OUT  NCHHSTP
Focus on 
C o m m u n i c a t i o n  
Science ,  H e a l t h  
M a r k e t i n g ,  and  
e C h a n n e ls
In FY 2008, NCHHSTP took a 
number of steps to increase the 
evidence base and support for its 
communication research programs 
and health communication and 
social marketing campaigns. The 
STD Program received intramural 
support for its research into com­
munication factors— including 
stigma and personal health 
beliefs—that may influence sexual 
health outcomes and health dis­
parities among African-Americans. 
NCHHSTP also awarded two 
grants to the Centers for Excel­
lence in Health Communication 
and Marketing at the University of 
Connecticut to study how young 
people might use mobile cell 
phone technology in viral market­
ing campaigns aimed at increasing 
awareness of the need for HIV 
testing.
These grants followed innovative 
marketing efforts in mobile 
media in FY 2008. NCHHSTP, 
in collaboration with the Kaiser 
Family Foundation (KFF) and 
National Center for Health 
Marketing’s eHealth Division, 
led CDC in building capacity 
for using mobile channels to 
reach young people at risk with 
prevention messages. For World 
AIDS Day 2007, NCHHSTP 
supported and promoted KFF’s 
short-message service that enables 
people to find HIV testing
Know your 
H IV  status?
Text: Your Zip Code 
To: Know It or 866948
To find HIV Test 
C e n te rs  n e a r  t o u . '■V'4
wwwiilvtest.org
locations near them by texting 
their zip code to “KNOWIT.” 
These efforts were taken a step 
further through an innovative 
partnership with the University 
of Georgia’s New Media Center. 
Students developed “personal 
public service announcements,” 
short video messages about the 
need for HIV testing, that were 
distributed nationally by Verizon
on its V-Cast network and through 
CDC’s YouTube channel, CDC 
MySpace, and other social media 
channels.
This year, NCHHSTP continued 
to advance its use of the Web 
and new media by launching 
“Health Protection Perspectives,” 
a blog in which CDC’s partners 
and other interested parties can 
exchange ideas for the prevention 
of HIV, Hepatitis, STD, and TB. 
CONNECTIONS, an email- 
based newsletter for partners, also 
advanced program collaboration 
by providing updates across the 
center’s programs. The projects 
highlighted here are among the 
many high-quality communica­
tion research efforts underway at 
NCHHSTP.
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A Year in Review:  
P r o g ra m
A c c o m p l is h m e n t s
T o ensure the greatest im­pact on the HIV/AIDS, STD, viral hepatitis, and 
TB epidemics, NCHHSTP uses a 
comprehensive, evidence-based ap­
proach to prevention that incorpo­
rates surveillance, research, preven­
tion interventions, and evaluation. 
NCHHSTP’s surveillance and 
research activities help to better 
define and understand the nature 
of the epidemics across the nation 
and inform the targeting and de­
velopment of prevention strategies. 
The center’s prevention interven­
tions and capacity-building efforts 
are based on behavioral, labora­
tory, and medical science and are 
designed to contain the spread of 
HIV/AIDS, STDs, viral hepatitis 
and TB. Program evaluation and 
policy research and development 
assess intervention effectiveness 
and refine prevention approaches.
The Office of Management and 
Budget rates all federal programs 
using a standard questionnaire 
called the Program Assessment 
Rating Tool (PART). The PART 
rating indicates how well a pro­
gram is performing so the public 
can see how effectively tax dollars 
are being spent. NCHHSTP’s 
comprehensive prevention pro­
grams have been rated “effective,” 
the top rating for federal pro­
grams. Programs that receive this 
rating set ambitious goals, achieve 
results, are well-managed, and 
improve efficiency.
In 2005, CDC established 
Health Protection Goals for the 
nation. NCHHSTP’s program 
areas are primarily represented 
in three of CDC’s four overarch­
ing Health Protection Goals: 
healthy people, healthy places, 
and global health. Following 
are examples of NCHHSTP 
programmatic activities and ac­
complishments in FY 2008, by 
goal area.
H e a l t h y  People  
in Every Stage  
of  Life
CDC’s primary mission is to 
reduce health risks at all stages 
of life, through the most ef­
ficient and effective means pos­
sible. CDC’s goals are focused 
on helping all people, and 
especially those at greater risk 
of health disparities, to achieve 
their optimal lifespan with the best possible quality of health in 
every stage of life. Following are 
some highlights of NCHHSTP’s 
key accomplishments and activities 
related to the goal area of healthy 
people in every stage of life.
P r o v id in g  a C le are r  
P ic tu re  of  t h e  HIV  
E p id e m ic
M e a s u r i n g  H IV  
Inc idence
Accurately tracking the HIV epi­
demic is essential to the nation’s 
HIV prevention efforts. However, 
monitoring trends in new HIV
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infections has posed a major chal­
lenge since the beginning of the 
epidemic, in part because many 
HIV infections are not diagnosed 
until years after they occur.
Now, new technology developed 
by CDC can be used to distin­
guish recent from long-standing 
HIV infections. CDC has applied 
this advanced technology—sero­
logic testing algorithm for recent 
HIV seroconversion (STARHS)— 
to develop the first national 
surveillance system that is based
on direct measurement of new 
HIV infections. This new system 
represents a major advance in HIV 
surveillance and allows for more 
precise estimates of HIV incidence 
(the annual number of new infec­
tions) than ever before possible.
CDC’s first estimates from this 
system, issued in August 2008, 
revealed that the HIV epidemic 
is—and has been—worse than 
previously known. Results indicate 
that approximately 56,300 new 
HIV infections occurred in the 
United States in 2006. This figure 
is roughly 40% higher than CDC’s 
former estimate of 40,000 infec-
tions per year, which was based 
on limited data and less precise 
methods.
The estimates of HIV infection 
from the STARHS system were 
published in the journal JAMA.
In coming years, this new surveil­
lance system will provide trend 
information that will allow better 
monitoring of the course of the 
epidemic and assessment of the 
impact of our nation’s HIV pre­
vention efforts.
A separate CDC historical trend 
analysis also published as part of 
the JAMA article suggests that 
the number of new infections was 
probably never as low as the previ­
ous estimate of 40,000 and has 
been roughly stable overall since 
the late 1990s. The new estimate 
does not represent an actual in­
crease in the number of new infec­
tions, but rather reflects the ability 
to more precisely measure new 
HIV infections.
H I V  N a m e - b a s e d  
Re p or t in g
In July 2005, CDC Director Dr. 
Julie Gerberding recommended 
that “all states conduct HIV 
reporting using the same name- 
based approach currently used for 
AIDS surveillance nationwide.” 
Use of confidential name-based re­
porting for HIV is consistent with 
all other infectious diseases report­
ing, including AIDS. As of April 
2008, all 50 states, District of 
Columbia, and 5 territories have 
adopted confidential, name-based 
HIV reporting.
CDC policy has been to report 
HIV infection and AIDS case sur­
veillance data only from areas con­
ducting confidential name-based 
reporting because this reporting 
has been shown to routinely 
achieve high levels of accuracy and 
reliability. Having all states col­
lect HIV information in the same 
manner will ensure that the na­
tion has reliable and valid data to 
monitor the scope of the epidemic; 
allow for planning and evaluation 
of prevention, care, and treat­
ment programs; and focus those 
programs on persons most at risk. 
CDC expects that the 2012 HIV/ 
AIDS Surveillance Report will 
capture HIV/AIDS surveillance 
data from all 50 states, the District 
of Columbia, and 5 territories.
H e i g h t e n e d  
N a t i o n a l  R esp onse  
to  t h e  On g o in g  
H IV /A ID S  Crisis 
A m o n g  A fr ican  
A m e r ic a n s
HIV remains a persistent and 
pervasive threat to the health, 
well-being, and human potential 
of many African Americans, who
14 N a t i o n a l  C e n t e r  f o r  H I V / A I D S ,  V i r a l  H a t  i t  i s , S T D d T P r e v e n t i o n
A YEAR IN REVIEW: Program Accomplishments
account for 45% of HIV/AIDS in­
fections, yet make up 12% of the 
U.S. population.
In March 2007, in response to the 
alarming HIV/AIDS epidemic, 
CDC launched an initiative 
termed the “Heightened National 
Response (HNR) to the Ongoing 
HIV/AIDS Crisis Among African 
Americans.”
In an effort to mobilize broader 
community action, leaders from 
many sectors were asked to join 
NCHHSTP in expanding efforts 
to address the HIV/AIDS epi­
demic among African Americans.
A total of 80 leaders representing 
the media, AIDS service organi­
zations, faith, health, and civic/ 
social organizations, the arts and 
entertainment industry, education, 
business, labor, and government 
attended the HNR launch event 
held March 8, 2007. A total of 
113 commitments to take a spe­
cific action to address the epidemic 
were made by the 80 leaders and 
organizations. As of September 
2008, 65 of the original commit­
ments have been completed and 
34 commitments are in progress.
In May 2008, NCHHSTP held a 
one-year anniversary meeting for 
H N R in Atlanta. More than 120 
leaders attended the meeting and 
made more than 150 new com­
mitments to stop the spread of 
HIV among African Americans. 
This important gathering of pub­
lic health and African American 
leaders added significant momen­
tum to H N R mobilization efforts. 
Many leaders exceeded the scope 
of the commitments made at the 
2007 partnership meeting and 
many new partners continue to 
join this important effort.
For example, platinum-selling 
singer/songwriter/producer Lyfe 
Jennings will launch a program in 
support of HNR named It’s Real. 
Preserve Your Lyfe! The program 
will occur in each of the 22 cities 
where Lyfe’s tour will be making 
stops. As part of the program, 
local health facilities will distrib­
ute “Lyfe Change” kits featuring 
important HIV/AIDS prevention 
and education resources, as well as 
copies of Lyfe’s song, “It’s Real,” 
which addresses the HIV/AIDS 
epidemic. Since the start of his 
career, Lyfe, whose third album 
Lyfe Change debuted at #1 on the 
Billboard R&B charts in April, 
has been particularly vocal about 
promoting HIV/AIDS awareness 
through his music.
Another example of a commit­
ment is that of Dr. Nelson L. 
Adams, President of the National 
Medical Association (NMA). Dr. 
Adams committed to increasing
HIV awareness and educational 
efforts by using print and elec­
tronic HIV/AIDS prevention 
communications more effectively 
and promoting HIV/AIDS aware­
ness, education, training, testing, 
and access during NMA meetings, 
which were held in Atlanta in July 
2008.
NCHHSTP has launched a 
monthly electronic newsletter that 
features updates on recent HNR 
activities and information about 
upcoming H N R events.
HIV  P r e v e n t io n  
A im e d  at  M e n  W h o  
Have  Sex W i t h  M e n
Surveillance data from 2003-2006 
show an overall increase in HIV/ 
AIDS diagnoses among men who
have sex with men (MSM), with 
the upward trend most sharply 
evident among younger MSM and 
African American MSM. MSM 
accounted for 72% of all new 
HIV infections among male adults 
and adolescents in 2006, even 
though only about 4% to 6% of 
male adults and adolescents in the
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United States identify themselves 
as MSM. The HIV incidence 
estimates confirm that gay and 
bisexual men of all races remain 
the group most heavily affected 
by HIV, accounting for 53% of 
all new infections. These recent 
overall increases in HIV diagno­
ses among MSM, coupled with 
racial disparities, strongly point 
to a need for enhanced efforts to 
identify and provide appropriate 
prevention and education services 
for MSM in general, and specific 
groups of MSM (e.g., those who 
are members of minority races/ 
ethnicities) in particular.
In 2008, NCHHSTP continued 
to support a variety of efforts 
aimed at improving HIV preven­
tion among MSM, including the 
following:
• Funding six sites to develop and 
test new behavioral interven­
tions for MSM. Funded sites 
will conduct small random­
ized trials. Four sites (Balti­
more, Chicago, Milwaukee, 
and New York City) focus
on African American MSM, 
while the other two sites 
(Miami and New York City) 
focus on Latino MSM.
• Supporting four sites (Los 
Angeles; New York City; Ra­
leigh, NC; and San Diego) to 
conduct formative research 
to develop interventions for 
methamphetamine-using MSM.
• Developing an Internet-based 
intervention that will be appro­
priate for all MSM. DHAP is 
working with the nonprofit or­
ganization Public Health Solu­
tions in New York City through 
its “Ground Breaking Interven­
tions” project to develop this in­
tervention, which will be tested 
in a five-arm randomized con­
trolled trial. By simultaneously 
testing a number of interven­
tions for MSM in small stud­
ies, DHAP hopes to identify 
multiple interventions that look 
promising to compete for fund­
ing for a larger randomized trial.
• Packaging additional evidence- 
based interventions (EBIs) 
for MSM or adaptations of 
EBIs, through its Replicating 
Effective Interventions (REP) 
projects. For example, d-UP!, 
an adaptation of the Popular 
Opinion Leader intervention 
for African American MSM, 
has been shown to reduce un­
protected anal intercourse by 
32.3% and unprotected recep­
tive anal intercourse by 44.5% 
at 12 months post-intervention. 
This adapted intervention 
will be available in late 2008, 
and funds will be provided 
to train capacity-building as­
sistance providers and to train 
more than 200 community- 
based organizations serving 
African American MSM.
• Providing $4 million to state 
and local health departments 
to support the development 
of plans for enhancing HIV 
prevention services for MSM.
R e c o m m e n d a t i o n s  
on P a r t n e r  Services
During FY 2008 CDC finalized 
its Recommendations for Partner 
Services Programs for H IV  Infection, 
Syphilis, Gonorrhea, and Chla­
mydial Infection, and published 
the new recommendations as a 
Morbidity and Mortality Weekly 
Report Recommendation and Re­
port on November 7, 2008. The 
recommendations are intended 
for health department program 
managers responsible for oversee­
ing HIV, STD, or integrated HIV/ 
STD programs. Partner services 
are a broad array of services that 
should be offered to persons with 
HIV infection, syphilis, gonor­
rhea or chlamydial infection and 
to their partners. These services 
include partner notification, coun­
seling and testing for HIV and 
other STDS, treatment or link­
age to medical care and linkage 
or referral to other services. The 
recommendations provide health 
department managers with broad 
policy suggestions and key con­
textual information that will assist 
them as they plan, implement, 
and evaluate their partner services 
programs.
Before the release of the new rec­
ommendations, two separate sets 
of guidelines governed partner ser­
vices for H IV  and for STDs: CDC’s 
1998 H IV  Partner Counseling and
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Referral Services Guidance and the 
Partner Services module of the 
2001 Program Operations Guide­
lines for STD Prevention. The 
new recommendations revise and 
integrate these older guidelines in 
an effort to improve the efficiency 
and efficacy with which partner 
services are delivered. Greater in­
tegration of prevention services at 
the client level will reduce missed 
opportunities to offer clients 
needed services when they access 
care, help eliminate duplication 
and other structural inefficien­
cies, and create cost savings while 
simultaneously realizing public 
health benefits.
E x p e d i t e d  P a r t n e r  
T h e r a p y
Expedited partner therapy (EPT) 
is the practice of providing treat­
ment to partners of persons 
diagnosed with an STD without 
requiring a clinical examination 
or encounter with those partners. 
With EPT, the patient delivers 
either medication or a prescription 
to the partner. In 2006, the CDC 
recommended EPT as a useful 
option for treating partners of pa­
tients diagnosed with chlamydia or 
gonorrhea.
NCHHSTP undertook policy 
initiatives to assist STD prevention 
programs with implementation 
of EPT. The Division of STD 
Prevention assessed the legal 
barriers to and facilitators of 
implementation of EPT at the 
state level. This legal research 
resulted in development of a 
web-based tool for local public
health practitioners interested 
in implementing EPT in their 
jurisdictions (http://www.cdc. 
gov/std/ept/legal/default.htm). 
Additional policy initiatives 
include collaborations with:
• the American Medical As­
sociation, which supported 
the practice of EPT through 
passage of resolutions at its 
June 2006 and November 2007 
House of Delegates meetings;
• the American Bar Association, 
which supported removal of 
state-level legal barriers to prac­
tice of EPT through passage
of a resolution at its August 
House of Delegates meeting;
• the Council of State Gov­
ernments to develop ma­
terials to educate state 
legislators about EPT.
I n f e r t i l i t y  
P r e v e n t io n
One of NCHHSTP’s key priori­
ties for STD prevention is increas­
ing chlamydia screening of young 
women outside of traditional 
public health settings. Annual 
chlamydia screening of sexually ac­
tive women 25 years and younger 
is recommended by CDC and 
other professional organizations 
to detect and treat women before 
chlamydia progresses to pelvic 
inflammatory disease, which can 
lead to infertility. The National 
Infertility Prevention Program, a 
collaboration between CDC and 
the Office of Population Affairs, 
funds chlamydia and gonorrhea 
screening and treatment services
for low-income, sexually active 
women attending family planning, 
sexually transmitted diseases, and 
other women’s healthcare clinics. 
However, a significant proportion 
of individuals screened or seeking 
medical care for STDs access ser­
vices through the private or non­
profit sectors.
In 2008, CDC recruited a Na­
tional Chlamydia Screening Co­
ordinator to lead an initiative to 
engage partners on this important 
reproductive health issue. In addi­
tion, a new National Chlamydia 
Coalition (NCC) was successfully 
launched on June 5, 2008 at a 
meeting attended by more than 
30 national organizations. Under 
the leadership of Partnership for 
Prevention, a Steering Committee 
of eight founding organizations 
planned for the meeting and 
recruited other national organiza­
tions with interests in reproductive 
and sexual health. The overall goal 
of NCC is to improve and protect 
the health of sexually active adoles­
cent and young adults by increas­
ing rates of hlamydia screening 
among young women.
NCHHSTP also collaborated 
with Partnership for Prevention 
on developing a review paper 
of the evidence supporting 
recommended adolescent clinical 
preventive services. Although 
the National Commission on 
Prevention Priorities ranked 
chlamydia screening as one of the 
most effective clinical preventive 
services, based on relative health 
benefits and cost-effectiveness, 
the service utilization remains 
low. NCHHSTP, NCC, and
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Partnership for Prevention 
will use this paper to broaden 
awareness among providers of 
the importance of adherence 
to chlamydia screening 
recommendations.
Other FY 2008 activities contrib­
uted to our national infertility 
prevention efforts. To broaden un­
derstanding of chlamydia and its 
sequelae, CDC held the Chlamyd­
ia trachomatis Immunology and
Control Expert Advisory Meet­
ing, which brought together 34 
chlamydia experts to identify and 
prioritize the key questions about 
chlamydia immunobiology that 
have implications for chlamydia 
control programs; identify answers 
to key questions or where more in­
formation is needed; and develop 
research priorities to address gaps. 
NCHHSTP also collaborated with 
colleagues in CDC’s Division of 
Reproductive Health to write and 
publish a White Paper on infertil­
ity prevention, detection, and 
management as a public health 
issue. The paper formed the basis
of a CDC Infertility Symposium 
held in September 2008 at which 
invited participants discussed a 
broad range of issues and identi­
fied steps toward developing a 
national public health plan for the 
prevention, detection, and man­
agement of infertility.
Using
C o m m u n i c a t i o n  
T e c h n o l o g y  
fo r  P r e v e n t io n  
of  Sexu al l y 
T r a n s m i t t e d  
Diseases
NCHHSTP scientists have been 
in the forefront of using new 
communication technologies to 
further STD control and preven­
tion and to promote sexual health. 
In collaboration with the National 
Coalition of STD Directors, the 
National Guidelines for Internet- 
based STD and H IV  Prevention 
were released in FY 2008. The 
guidelines provide state and lo­
cal health departments and local 
community-based organizations 
with tools and best practices for 
using the Internet as a tool for the 
control and prevention of STDs 
and the promotion 
of sexual health. The 




and include sections on 
Internet-based partner 
services, outreach, and 
health communications.
In addition, the CDC STD Tech­
nology Center of Excellence devel­
oped and launched an STD pre­
vention professional networking 
website, STD Prevention Online, 
that provides both timely STD 
prevention information and an 
opportunity for STD prevention 
professionals to interact on line, 
share best practices and materials, 
and collaborate on new interven­
tions. The website, www.stdpre- 
ventiononline.org is updated daily 
and enrolled over 1300 members 
in the first 8 months of operation.
Other innovations were conducted 
to support STD Awareness Month 
in April 2008. The HIVtest.org 
website (www.hivtest.org) was 
enhanced and expanded to include 
search results for STD testing 
locations by zip code; previously 
the site returned only information 
about HIV testing locations. CDC 
also introduced STD-focused 
electronic greeting cards (e-cards), 
which are available to both the 
general public and state and local 
health departments (www.cdc.gov/ 
std). Finally, NCHHSTP released 
the findings of the multi-site Safe 
in the City waiting room video 
intervention trial, which showed 
an almost 10% reduction in new
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STDs among STD clinic patients 
who were exposed to the video.
The video can be easily integrated 
into the clinic waiting room, re­
quires very little staff time to set 
up with no disruption to clinic 
flow, and requires no counseling or 
small-group facilitation. NCHH- 
STP is actively supporting its use 
through multiple distribution 
channels.
Syphi l is  
E l im in a t i o n
To continue the success of the 
Syphilis Elimination Effort initi­
ated in 1999 to eliminate syphilis 
in the United States, NCHHSTP 
implemented several new activi­
ties in FY 2008. First, to improve 
monitoring of syphilis elimination 
activities and progress toward 
meeting elimination objectives, 
beginning in FY 2008, syphilis 
elimination programs were re­
quired to use an evidence-based 
action plan to guide the collection 
of information on the target popu­
lations, interventions provided,
resources allocated, and outcomes. 
For FY 2008, programs submitted 
evidence-based action plans, based 
on local morbidity data. The plans 
focused on target populations ex­
periencing the highest burdens of 
infectious syphilis. MSM, African 
Americans, incarcerated persons, 
and Latino populations were 
among the priority groups.
Second, a new integrated Inter­
view Record, jointly developed by 
the Division of STD Prevention 
and the Division of HIV/AIDS 
Prevention, was introduced. The 
record is designed for use in both 
STD and HIV prevention pro­
grams to support partner services. 
It provides a useful tool for syphi­
lis elimination programs with sig­
nificant syphilis morbidity among 
MSM. Two new data fields on the 
Interview Record are particularly 
useful to note: 1) a data field for 
sex of sex partner, an important 
element in understanding the na­
ture of the syphilis epidemic at the 
local level; and 2) a data field for 
indicating whether persons with 
syphilis met their partners through 
the Internet. This is significant 
because the Internet is a venue 
where MSM seek sex partners, 
and public health programs are 
successfully using the Internet as 
a tool for notification of potential 
infection and connecting partners 
to services. Since implementation 
of the new Interview Record, 43 
states are now reporting gender of 
sex partner, providing more precise 
data on the nature of the syphilis 
epidemic, both nationally and lo­
cally.
Finally in FY 2008, CDC issued 
clarifying guidance about use of 
various syphilis testing algorithms, 
based on an analysis of testing 
algorithms used by four New York 
City laboratories. The analyzed 
algorithms reversed the traditional 
order of laboratory testing for 
syphilis; thus first testing with 
a treponemal test, followed by 
a non-treponemal test in cases 
found to be initially reactive. Re­
versing the order was found to 
be cost-saving, but could lead to 
confusion about interpretation 
and clinical management of the 
patient. The clarification will lead 
to cost-savings for syphilis elimina­
tion programs, and standardize 
interpretation and management of 
patients.
C o n t ro l  and  
P r e v e n t io n  of  
H e p a t i t i s
NCHHSTP Helps  
I d e n t i f y  H e p a t i t i s  C 
O u t b r e a k  a t  a N e v a d a  
Clinic
NCHHSTP’s Division of Viral 
Hepatitis (DVH) epidemiology 
and laboratory staff members 
played a critical role in identifying 
an outbreak of Hepatitis C at a 
Nevada endoscopy clinic in 2008.
Six patients contracted hepatitis C 
during July-December 2007 after 
endoscopy and were found to have 
virtually identical viral sequences; 
subsequently, 40,000 patients were 
notified about their risk of expo­
sure to bloodborne pathogens. The
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transmission of hepatitis C was 
associated with reuse of syringes 
that contaminated multiply used 
vials of anesthetic. DVH epidemi­
ologists and laboratory scientists 
collaborated in the investiga­
tion with the CDC Division of 
Health Care Quality Promotion, 
Nevada State Health Division, 
and Southern Nevada Health 
District. Preliminary results were 
published in M M W R  (May 16, 
2008;57(19);513-517).
An Epidemic Intelligence Service 
officer from DVH assisted with 
and provided advice for the state’s 
efforts, including interviewing and 
collecting specimens from identi­
fied hepatitis C patients for analy­
sis at CDC; investigating infection 
control procedures at the clinic 
that was the subject of the investi­
gation; and conducting appropri­
ate data collection, notification, 
and testing procedures for other 
patients who were potentially ex­
posed at the clinic in question.
The viral hepatitis laboratory was 
responsible for conducting the 
initial molecular analysis that con­
firmed the association of hepatitis 
c virus infections among patients 
seeking care at the endoscopy clin­
ic. In addition, the epidemiologic
analysis and technical assistance 
offered by CDC was instrumental 
to subsequent actions taken by 
local public health officials to pre­
vent further spread of disease and 
notify those potentially exposed.
The Division of Viral Hepatitis is 
working with partners to develop a 
comprehensive approach involving 
better viral hepatitis surveillance 
and case investigation, healthcare 
provider education and training, 
professional oversight, licensing, 
and public awareness, to prevent 
out-of-hospital healthcare-related 
viral hepatitis transmission.
R e c o m m e n d a t i o n s  
on H e p a t i t is  B Virus  
In fe c t io n
NCHHSTP published new rec­
ommendations for identification 
and public health management of 
persons with chronic hepatitis B 
virus infection in the September 
19, 2008 issue of MM W R Recom­
mendations and Reports. This is 
the first time CDC has published 
hepatitis testing recommenda­
tions as a stand-alone report.
This report compiles and updates 
recommendations for hepatitis B 
testing previously made by CDC. 
The recommendations serve as a
resource for public health officials, 
organizations, and health care 
professionals involved in the devel­
opment, delivery, and evaluation 
of prevention and clinical services. 
Partners were instrumental in the 
development and dissemination of 
recommendations.
H e p a t i t is  B Vaccine  
In i t i a t i v e
Eliminating viral hepatitis B in the 
United States will require immu­
nization of adults who are at high 
risk for hepatitis B. NCHHSTP 
worked with the National Center 
for Immunization and Respiratory 
Diseases (NCIRD) and CCID 
to initiate a Hepatitis B Vaccine 
Initiative in FY 2007. Section 317 
Immunization Grant Funds to the 
states were used for this initiative.
The initiative reaches more high­
risk adults by making vaccine 
available in public health venues, 
including HIV clinics, STD clin­
ics, and correctional facilities. In 
the first year, $20 million of im­
munization program funds were 
awarded to 51 state and local 
health departments to purchase 
hepatitis B vaccine to immunize 
high-risk adults. By 2008, 1,500 
public health settings had par-
CDC Home Search Health Topics A-Z
MMWR
Recommendations and Reports
Septem ber 19, 2008 I 57(RR08):1-20
Recommendations for Identification and Public Health Management of 
Persons with Chronic Hepatitis B Virus Infection
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CD C’s contributions, in partner­
ship with ministries of health 
and its U.S. Government col­
leagues in the large interagency 
PEPFAR initiative, have helped 
to achieve the following results:
• 1.73 million men, women 
and children have received 
antiretroviral therapy.
• 12.7 million pregnant women 
have participated in pre­
venting mother-to-child 
transmission of HIV.
• 194,000 infant infections 
have been prevented.
ticipated in the initiative. A total 
of 151,574 doses of hepatitis B 
vaccine were ordered during the 
first and second quarters, and ap­
proximately 69,900 doses were 
administered.
W H O  C o l l a b o r a t i n g  
C e n t e r
The Pan American Health Organi­
zation/World Health Organization 
has redesignated NCHHSTP’s 
Division of Viral Hepatitis as a 
PAHO/WHO Collaborating Center 
for Reference and Research on Viral 
Hepatitis through 2012. The Divi­
sion of Viral Hepatitis provides 
member states with epidemio­
logic, surveillance, laboratory, and 
programmatic data and technical 
assistance and assists in promot­
ing scientific and programmatic 
recommendations and strategies 
for the prevention, control, and 
management of viral hepatitis.
H e a l t h y  People  
in a H e a l th y  
Wor ld
CDC spearheads efforts to 
improve global health through 
medical technology, interna­
tional coalitions, government 
interventions, and basic be­
havior changes. NCHHSTP 
contributes to this global effort 
via international research in HIV/ 
AIDS, viral hepatitis, STDs, and 
TB, through its Global AIDS 
Program (GAP) and through tech­
nical assistance in areas such as TB 
control.
G lo ba l  AIDS  
P r o g ra m
GAP is a proud partner in the 
President’s Emergency Plan for 
AIDS Relief (PEPFAR), a mul­
tifaceted approach to combating 
the HIV/AIDS in more than 
120 countries around the world. 
As part of PEPFAR, GAP works
alongside other dedicated partners, 
both governmental and non­
governmental, to provide direct 
scientific and technical assistance 
to ministries of health, partner or­
ganizations, and other U.S. Gov­
ernment agencies. GAP develops 
cutting-edge science and translates 
it to public health service deliv­
ery, by strengthening ministry of 
health capacity to build self-reliant 
national public health systems.
In FY 2008, PEPFAR was extend­
ed another five years with the sign­
ing of the Tom Lantos and Henry 
J. Hyde United States Global 
Leadership Against HIV/AIDS, 
Tuberculosis, and Malaria Reau-
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thorization Act. CDC has lever­
aged the agency’s core strengths to 
make unique contributions to the 
PEPFAR initiative over the past 
five years and is poised to play an 
even greater role in the next five 
years of this ground-breaking ef­
fort.
During the first five years of 
PEPFAR, CDC:
• Provided leadership on over 
125 studies, ensuring scientifi­
cally sound interventions;
• Helped build sustainable labora­
tory infrastructure to respond 
to HIV and other diseases;
• Helped implement innova­
tive surveillance systems and 
data for epidemiologically 
driven decision-making;
• Spearheaded HIV Prevention 
in Care and Treatment Settings 
for HIV-infected individu­
als in sub-Saharan Africa;
• Partnered with HRSA to sup­
port massive scale-up of anti­
retroviral treatment to adults 
and children and increase 
pregnant women participation 
in programs to prevent mother- 
to-child transmission; and
• Researched and developed 
the Basic Care Package, a 
package of interventions that 
is designed to minimize the 
susceptibility of HIV-positive 
persons to common opportu­
nistic infections and illnesses 
spread by unsanitary water.
CDC will continue to play a lead­
ership role in improving health
systems, treatment and prevention, 
laboratory capacity building, sur­
veillance, human capacity develop­
ment, and data-driven program 
decision-making in the next phase 
of PEPFAR. The PEPFAR reau­
thorization legislation also calls for 
CDC leadership in the areas of:
• Program monitoring;
• Impact evaluation re­
search and analysis;
• Operational research;
• Microbicide research and 
development; and
• Malaria operations and 
implementation research.
CDC’s efforts will be key to meet­
ing the new 10-year program goals 
for PEPFAR, which include treat­
ment for at least 3 million people, 
the prevention of 12 million new 
infections, and care for 12 mil­
lion people, including 5 million 
orphans and vulnerable children. 
Specifically, CDC will play an en­
hanced role in:
• Prevention, including a renewed 
emphasis on prevention of 
mother-to-child transmission;
• Improvement of diagnostic 
laboratory capabilities across 
HIV/AIDS, TB, and malaria;
• Meeting the goal of train­
ing and retaining 140,000 
health care workers; and
• Strengthening of health systems, 
in consultation with the World 
Health Organization (WHO).
H I V  Prevent ion:  M a l e  
Circumcision
As a result of research funded by 
the National Institutes of Health, 
evidence from several African 
countries has now shown that 
medically provided adult male 
circumcision can decrease the rate 
of heterosexual HIV acquisition in 
men. GAP is providing technical 
assistance to ministries of health 
to develop national policies and 
strategic plans, conduct situational 
assessments, and implement and 
evaluate male circumcision service 
delivery programs.
Working collaboratively with other 
U.S. government agencies, GAP 
is supporting the development of 
technical guidance and tools as 
well as monitoring and evaluation 
systems. Furthermore, GAP is 
helping the international com­
munity, working with UNAIDS 
and W HO, to define priorities 
and develop guidance on the key 
service components, communica­
tion strategies, quality assurance 
measures, and operational research 
priorities for male circumcision 
programs.
GAP worked closely with the 
government of Kenya in 2008, 
providing technical assistance on 
policy and strategic plan develop­
ment, design of service delivery 
models, and the development of a 
monitoring and evaluation system. 
With GAP support, Kenya is now 
preparing for an innovative meth­
od of service delivery—portable 
male circumcision services to reach 
men in rural areas. GAP is also 
jointly supporting, with the Gates
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Foundation, a training center in 
Kenya to train public and private 
sector providers in male circum­
cision. Thus far, the center has 
trained 115 medical and clinical 
officers, nurses, and counselors.
Ear ly  I n f a n t  D iagnos is
Worldwide, children account for 
almost 14% of all new HIV infec­
tions, but make up only 7% to 9% 
of cases being treated. Early infant 
diagnosis via testing of infants 
born to HIV-infected mothers 
in the infants’ first months of life 
enables HIV-infected infants to 
receive timely and appropriate care 
and treatment, often before the 
onset of rapid disease progression. 
Without treatment, up to 50% 
to 60% of HIV-infected infants 
die by 2 years of age. Early infant 
diagnosis also has the potential to 
improve the effectiveness of pre­
vention of mother-to-child HIV 
transmission programs by promot­
ing follow-up after delivery and 
providing essential data to assess 
the impact of interventions de­
signed to prevent mother-to-child 
transmission of HIV.
Through PEPFAR, GAP is help­
ing build capacity in multiple 




ogy. With the 
simple prick 
of an infant’s 
heel, toe, or 
finger, whole 
blood can be 
placed on a 
filter paper 
card to dry, 
creating sam­
ples which 
are stable for 
relatively long 
periods without refrigeration and 
are light and simple to transport 
by courier or vehicle to a lab for 
testing. In 2008, GAP strength­
ened laboratory networks for 
early infant diagnosis, developed 
demonstration protocols and test­
ing algorithms, helped implement 
quality assurance/quality control 
programs, and conducted emerg­
ing infectious disease training of 
laboratory technicians and health 
care providers.
Furthermore, GAP has developed 
training materials on pre- and 
post-test counseling to caregivers, 
including training to improve care, 
treatment, and other referral ser­
vices for vulnerable HIV-exposed 
and HIV-infected infants, and has 
built and strengthened data moni­
toring and feedback systems to 
support early infant diagnosis and 
associated programs. With GAP’s 
leadership, early infant diagnosis 
is now being implemented in 13 
countries in Africa and 2 countries 
in the Caribbean region.
I n n o v a t iv e  Kenya AIDS  
I n d i c a t o r  Study
In countries with large general­
ized HIV epidemics, nationally 
representative HIV prevalence 
data are critical for resource and 
program planning and for moni­
toring the impact of the epidemic. 
The Kenyan Government, with 
assistance from GAP, implemented 
an innovative national population- 
based household survey (~10,000 
households) that not only mea­
sured HIV prevalence, but also 
the prevalence of diseases that 
interact with HIV, such as syphilis, 
herpes simplex virus 2, and viral 
hepatitis. They also measured CD4 
cell counts among persons who 
tested HIV positive to estimate the 
number of HIV-positive persons 
in need of treatment.
The preliminary results of the 
2007 Kenya AIDS Indicator Sur­
vey, released in July 2008 by the 
Government of Kenya, showed 
that an estimated 1.4 million 
adults in Kenya are infected with 
HIV. Other preliminary findings 
include:
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• Among adults age 15-64,
7.4% are infected with HIV, 
a slight increase from the 
6.7% prevalence recorded 
in the 2003 Kenya Demo­
graphic and Health Survey.
• Women (8.7%) continue to be 
disproportionately infected with 
HIV compared to men (5.6%).
• Prevalence among adults 
age 50-54 is 8% and de­
clines to less than 3% 
among adults ages 60-64.
After successful completion of the 
survey, survey partners in Kenya 
focused on laboratory testing, a 
return-of-results exercise, and data 
entry of survey responses.
I n t e r n a t i o n a l  
T u be rc u lo s is  
C o n t ro l  Techn ica l  
Ass is tance
Because TB kills 1.6 million a 
year worldwide and because most 
cases of TB in the United States 
are among foreign-born persons, it 
is critical for the United States to 
assist in international TB control. 
NCHHSTP’s Division of Tuber­
culosis Elimination (DTBE) 
and, for PEPFAR-related 
activities, GAP provide leader­
ship and technical assistance 
in controlling TB internation­
ally. In FY 2008, DTBE staff 
provided technical assistance 
in 40 countries. CDC’s global 
technical assistance for TB 
includes:
• Deploying outbreak 
response teams
• Improving access to TB drugs
• Developing TB test­
ing standards
• Building capacity of 
health care providers
• Collaborating with other 
international partners to de­
velop and implement the global 
plan to combat XDR TB
• Providing technical assistance 
to expand program capacity
• Supporting TB communica­
tion and education efforts.
In addition to working closely 
with ministries of health in other 
countries, CDC works with other 
federal agencies and with multilat­
eral organizations such as W HO 
and the International Union 
Against Tuberculosis and Lung 
Disease; foundations, including a 
Bill and Melinda Gates Founda­
tion-funded collaboration and the 
Foundation for Innovative Diag­
nostics; and non-governmental 
organizations. CDC is a found­
ing member of the W HO Stop 
TB Partnership, a global effort of 
more than 500 governmental and 
non-governmental organizations,
housed by W HO. Members of the 
Stop TB Partnership work toward 
achieving the 2006-2015 Mil­
lennium Development Goals of 
reducing global TB deaths by 50% 
and the number of persons suffer­
ing from TB by 50%.
I n t e r n a t i o n a l  
S e x u a l l y  
T r a n s m i t t e d  
Disease  P r e v e n t io n  
Effor ts
Efforts to leverage opportunities 
for global STD prevention contin­
ued in FY 2008 with four signifi­
cant activities. First, NCHHSTP 
conducted program assessments of 
STD prevention services in U.S. 
Affiliated Pacific Islands (USAPI). 
NCHHSTP hosted a two-day 
planning meeting to develop an 
action plan for improving STD 
prevention capacity in the USAPI, 
based on findings from the pro­
gram assessments. NCHHSTP 
also initiated collaborations with 
Secretariat of the Pacific Com­
munities, W HO, United Nations 
Population Fund, and Pacific Is­
land Health Officers Association.
Efforts to enhance support 
STD prevention in the 
USAPI include development 
of STD case definitions and 
program guidelines; identifi­
cation of training and profes­
sional development needs; 
increased and more focused 
communications with local 
health officers; develop­
ment of a multidisciplinary 
working group that meets
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regularly to support specific Pa­
cific Islands issues; and continued 
communications with other CDC 
Divisions working in the Pacific 
Islands to ensure integration of ap­
proaches whenever possible.
Secondly, NCHHSTP continued 
its collaboration on the W HO 
initiative to eliminate congenital 
syphilis. Congenital syphilis is 
a serious public health problem 
globally, accounting for an esti­
mated 1.5 million cases each year 
and resulting in up to 750,000 
perinatal deaths, in addition to 
other significant perinatal morbid­
ity. Congenital syphilis can be 
prevented by serological screening 
for syphilis during pregnancy and 
prompt treatment of those women 
found positive with intramuscular 
penicillin. However, fragmented 
antenatal health services, lack of 
awareness of the burden and sig­
nificant public health outcomes of 
congenital syphilis, and limited re­
sources for screening have allowed 
this old disease to continue to 
cause substantial health problems 
in many developing countries.
In FY 2008, NCHHSTP worked 
closely with W H O  to develop 
surveillance, monitoring, and 
evaluation strategies for measuring 
the impact of the global initiative, 
as well as a research agenda to sup­
port the initiative. Additionally, 
CDC worked with W H O  and 
other international partners to 
develop an investment case study 
to identify funding and other 
resources to support the global 
initiative for the elimination of 
congenital syphilis as a public 
health problem. The investment
case study will be finalized in Fall 
2008. Finally, NCHHSTP col­
laborated with the World Bank 
to develop two documents pro­
moting global STD control as an 
important development strategy; 
both documents had a special em­
phasis on eliminating congenital 
syphilis.
Third, a point-of-care rapid 
syphilis test is currently being field 
tested in international settings in 
collaboration with the W H O  STD 
Diagnostics Initiative. The low- 
cost, user-friendly test is based on 
a patented technique developed in 
CDC’s STD laboratory. Using two 
antigens (both non-treponemal 
and treponemal), the test is a 
significant improvement over cur­
rently available rapid tests, which 
use only a single treponemal anti­
gen. This test could prove to be a 
useful tool for expanding antenatal 
screening to prevent congenital 
syphilis in the developing world 
and could also enhance screening 
of high-risk populations in the 
United States.
Finally, antimicrobial-resistant 
gonorrhea is a growing problem 
both domestically and internation­
ally. NCHHSTP supported W HO 
in 2008 to strengthen its regional 
gonococcal surveillance program, 
with special emphasis on the 
Western Pacific Region, where the 
emergence of further drug resis­
tance is most likely to occur.
H e a l t h y  People  
in H e a l t h y  Places
CDC is working hard to ensure 
that the places we live, work, and 
play have safe, healthy environ­
ments. Controlling TB in com­
munities is one of the ways CDC 
addresses this goal.
T u be rc u lo s is  
M o r b i d i t y  at  A l l ­
t i m e  Low in 2 0 0 7
In 2007, TB morbidity was at an 
all-time low in the United States, 
with 13,293 new cases reported in 
data released in FY 2008. This rep­
resents the 14th consecutive year 
of decline in reported TB cases.
The average annual percentage 
decline in the TB rate slowed from 
6.6% per year during 1993-2002 
to 3.3% during 2003-2007. For­
eign-born and ethnic minorities 
bear a disproportionate burden of 
U.S. TB cases. The percentage of 
TB cases in foreign-born persons 
in the United States increased 
from 22% of reported cases in 
1986 to 58% in 2007. U.S.-born 
blacks make up almost half (45%) 
of all TB cases among U.S.-born 
persons.
H e p a t i t i s  B/C 
T e s t in g  for  
T u be rc u lo s is  
P a t ie n t s  in Cook  
C o u n ty ,  I l l ino is
Liver damage and viral hepati­
tis are long-standing and often
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treatment-limiting concerns for 
patients with latent TB infection 
or TB disease. Drug-induced 
liver injury may occur with all 
recommended TB regimens, so 
monitoring for this effect is a nec­
essary element of anti-TB therapy. 
Because testing for liver damage is 
an integral part of TB treatment, 
a natural opportunity exists for 
integrating CDC programs that 
address TB and Hepatitis.
The Illinois Department of Health 
implemented a study to provide 
hepatitis B and C tests for patients 
who are undergoing treatment for 
either latent TB infection or TB 
disease. The goal is to establish 
baseline hepatitis seropositivity 
rates for the population served in 
its jurisdiction. An NCHHSTP 
public health advisor assigned to 
Illinois supervised the project, 
collaborating with the Illinois 
TB Program, the American Lung 
Association, the University of 
Illinois-Chicago, and the Subur­
ban Cook County TB Sanitarium 
District. Activities included work­
ing with partners to complete the 
study design, recruiting partners in 
hepatitis programs 
to accept TB 
patient referrals 









dures for TB and 
hepatitis B and C, 
training nurses on
the study protocol, and developing 
hepatitis education materials to 
share with TB patients.
C o m m u n i t y  
C o l l a b o r a t i o n  
to  Ad d ress 
Tub e rc u lo s is  in 
A fr ica n  Am eri  cans  
in C en t ra l  G e o r g ia
African-Americans suffer dispro­
portionately from TB. African- 
Americans born in the United 
States represent 44% of TB cases 
in U.S.-born persons, and account 
for approximately 19% of the 
overall national case total. TB rates 
among US born African Ameri­
cans are 10.2 cases per 100,000.
In 2004, to help characterize 
how transmission of TB occurs, 
NCHHSTP initiated a universal 
genotyping project in all state and 
local programs and laboratories. 
Genotyping enables the identifica­
tion of TB strains with matching 
DNA but no apparent epidemio­
















investigations to look for potential 
links between the patients. Al­
though no specific links were iden­
tified, some of the patients could 
have interacted with one another 
in situations involving substance 
or alcohol abuse, construction 
work, incarceration, or living in 
relatively close proximity to each 
other.
To be sure that TB transmission 
would be halted in any of these 
circumstances, the Georgia TB 
program, which is funded by 
CDC’s state TB cooperative agree­
ment program, developed a project 
to raise TB awareness in the affect­
ed health districts. The goals were 
to foster better communications 
among the local public health 
department and the health care 
sector in the health district and 
provide TB education to residents 
of targeted zip code areas where 
cases had been found.
The Georgia TB program con­
ducted a survey that assessed at- 
risk residents’ TB knowledge and 
enablers or barriers to accessing 
TB services in the district. Results 
showed that residents needed 
transportation to access services, 
TB education and outreach efforts, 
and additional TB testing loca­
tions around the community.
To address these findings, the 
Georgia TB program held a meet­
ing with community partners to 
elicit support for more TB educa­
tional and testing opportunities in 
the neighborhoods. The partners 
now meet quarterly to discuss TB 
and other health disparities.
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E x p a n d in g  
t h e  Reach of  
P r e v e n t i  on and  
I m p r o v i n g  H e a l t h  
in C o r r e c t io n a l  
S e t t in g s
The U.S. Bureau of Justice Statis­
tics reported in 2006 that almost 
7.3 million persons were under 
correctional supervision. Approxi­
mately 2,259,000 prisoners were 
held in federal or state prisons or 
local jails and 5,035,200 million 
persons were on probation or pa­
role. Many persons in correctional 
settings have multiple risk factors 
for HIV, STD, viral hepatitis, and 
TB, and the prevalence for these 
diseases is often higher than in the 
general population.
Inmates bring complex social 
problems and health issues with 
them from the community, and 
criminal justice settings provide an
excellent opportunity for conduct­
ing integrated health screening 
and testing and for providing 
medical treatment and prevention 
services. Criminal justice settings 
can also play a critical role in as­
sisting inmates with linkage to care 
as they transition back into the 
community.
NCHHSTP has formed the 
Center Corrections Workgroup 
tasked to address the challenges of 
facilitating health equity within
this population. The overarching 
mission of this workgroup is to 
address issues related to the pre­
vention and control of HIV, STD, 
Viral hepatitis, and TB among in­
carcerated persons. The workgroup 
facilitates collaboration within 
NCHHSTP and across CDC to 
address health disparities and to 
promote integration of programs 
for incarcerated populations. In 
early 2009, the workgroup will 
host a Public Health and Cor­
rections consultation designed 
to create collaborations and new 
partnerships and develop strategies 
to promote an effective corrections 
agenda.
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A Year in Review:
S c ie n t i f i c  F ind ings
N CHHSTP conducts extensive biomedical and behavioral research 
to better understand the complex 
factors that lead to epidemics. 
Research is an important part of 
CDC’s comprehensive approach
to prevention, and excellence in 
science is a strategic priority. This 
priority mandates that we practice 
evidence-based science grounded 
in sound peer-reviewed research 
and that we assure a strong science 
base for public health action.
NCHHSTP conducts or supports 
research in areas such as diagnostic 
tests, microbicides, vaccines, and 
behavioral research focused on 
eliminating health disparities. All 
extramural and intramural re­
search activities conducted or sup­
ported by NCHHSTP are subject 
to external peer review, ensuring 
rigor and quality and that research 
funds support the most meritori­
ous research ideas and projects.
External peer review improves 
our science by providing expert 
feedback on quality, productivity, 
science, and direction.
Three advisory boards provide peer 
review of NCHHSTP programs 
on a regular basis. The Advisory 
Council for the Elimination of 
Tuberculosis provides advice on 
NCHHSTP TB prevention and 















cutting program review, focusing 
on all CCID programs, including 
those of NCHHSTP. In addition, 
external peer review panels are 
periodically convened to review 
NCHHSTP research programs. In 
June 2008, an external panel re­
viewed the Division of HIV/AIDS 
Prevention Laboratory Branch’s 
intramural research programs.
Further, research findings are pub­
lished in peer-reviewed journals. 
NCHHSTP staff published or 
have in press a number of journal 
articles, book chapters, books, 
guidelines, and other publications. 
Below are some highlights from 
FY 2008.
NCHHSTP is also committed to 
mentoring young scientists inter­
ested in epidemiologic and pre­
vention research. The extramural 
Minority HIV/AIDS Research Ini­
tiative (MARI), initiated in 2002, 
creates partnerships between CDC 
epidemiologists and researchers 
who are members of minority 
races and ethnicities and who 
work in communities of color. 
MARI funds epidemiologic and 
prevention studies of HIV in com­
munities of color and encourages 
the career development of young 
investigators. The center also has a 
number of Epidemic Intelligence 
Service (EIS) officers, with six offi­
cers joining the center in FY 2008. 
The EIS is the country’s critical 
epidemiology training service, 
working to combat the causes of 
major epidemics.
H e a l t h y  P e o p le  in 
Every  S tage  of  Life
NCHHSTP released two sig­
nificant products promoting 
evidence-based HIV behavioral in­
terventions in 2008: the Updated 
Compendium of Evidence-based 
Interventions and the Tiers of Evi­
dence Framework. These products 
represent a major advance in HIV
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prevention science and will make 
a significant impact in CDC’s ef­
forts towards evidence-based HIV 
prevention efforts.
The Updated Compendium pro­
vides a comprehensive, up-to-date 
list of scientifically proven HIV 
behavioral interventions reducing 
HIV/STD risk and incidence that 
can be used to guide programmat­
ic planning throughout the United 
States. A total of 57 evidence- 
based individual-level and group- 
level interventions (EBIs) pub­
lished between 1988 and 2008 are 
currently posted on the Prevention 
Research Synthesis web site. The 
majority of EBIs are designed for 
racial/ethnic minority groups who 
are disproportionately affected by 
the HIV epidemic. NCHHSTP 
is currently identifying evidence- 
based community-level interven­
tions and continuously assesses 
newly published behavioral inter­
ventions.
The Tiers of Evidence framework 
identifies and describes four levels 
of evidence for an intervention’s 
efficacy, based on different kinds 
of evaluation designs. The frame­
work was developed to supple­
ment the Updated Compendium 
and to help the HIV prevention 
community understand CDC’s 
evidence-based HIV prevention 
efforts. The framework comprises 
two evidence-based and two theo­
ry-based tiers. Tier I contains ‘Best 
EBIs,’ those with the most rigor­
ous study design, implementation, 
and analysis and with the strongest 
evidence for reducing HIV/STD 
risk or incidence. Tier II contains 
‘Promising EBIs,’ those that have
been rigorously evaluated and have 
significant findings. Tier III in­
cludes theory-based interventions 
with positive outcome monitoring, 
and Tier IV consists of theory- 
based interventions with positive 
process evaluation. The Tiers 
framework can help guide funding 
decisions around which interven­
tions should be supported through 
federal, state, and local funds. It 
also provides important guidance 
to community-based organizations 
for improving their evaluation of 
locally developed interventions.
Stu d y Assesses  
P re v a le n c e  
of  Sexu al l y 
T r a n s m i t t e d  
I n f e c t io n s  
A m o n g  F e m a le  
A d o le s c e n ts
In FY 2008, CDC released a study 
indicating that one in four (26%) 
female adolescents in the United 
States has at least one of the most 
common sexually transmitted 
infections (STIs). The study is the 
first to examine the combined na­
tional prevalence of common STIs 
among adolescent women in the 
United States.
Data on 838 female adolescents 
(aged 14-19 years) who partici­
pated in the 2003-2004 National 
Health and Nutrition Examina­
tion Survey, a continuous annual 
study that examines a nationally 
representative sample of the U.S. 
household population, were 
analyzed to assess a broad range 
of health issues. The teens were
tested for human papillomavirus 
(HPV) infection, chlamydia, her­
pes simplex virus type 2 (HSV-2) 
infection, and trichomoniasis. The 
authors examined high-risk HPV 
types, including 23 types that are 
known to cause cancer, and the 
two types that cause most genital 
warts.
Based on the overall STI preva­
lence of 26%, the authors estimate 
that about 3.2 million adolescent 
females in the United States are 
infected with one of these STIs. 
Most of these were HPV infec­
tions. Total prevalence might be 
slightly higher than these estimates 
indicate, because some STIs— 
including syphilis, HIV, and 
gonorrhea—were not included in 
the analysis; however, the preva­
lence of these STIs is low in this 
age group.
S tu d y  E x a m ines  
P r e v a le n c e  of  
H e t e r o s e x u a l  Anal  
and Ora l  Sex
An NCHHSTP study examined 
the correlates of heterosexual anal 
and oral sex in the general popula­
tion, and found a high lifetime 
prevalence of anal sex (>30% of 
sample) and oral sex (>60% of 
sample) and relatively low levels of 
condom use in various subgroups. 
An association between anal sex 
and viral STDs was found among 
women and Hispanic and black 
men. This suggests that physicians 
and other public health practi­
tioners should consider assessing 
anal and oral sex practices when
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determining patients’ STI/HIV 
risk (e.g., during sexual risk assess­
ments). Incorporating messages 
about the risks of anal and oral sex 
could reduce potential unintended 
consequences that may result 
when interventions among hetero­
sexuals solely focus on vaginal sex.
C h la m y d ia  
S c re e n in g  and  
Test ing
An NCHHSTP study identified 
missed opportunities for 
chlamydia testing of young 
women at ambulatory care visits 
during pelvic examinations, Pap 
tests, and urinalyses. These types 
of encounters can be targeted for 
the development of structural 
interventions that can result in 
increased chlamydia screening.
The study also identified 
physician specialties— obstetrics 
and gynecology and primary 
care— that should be targeted 
for interventions to increase 
screening rates. Further, chlamydia 
screening data may be used to 
track rates over time, to monitor 
the effectiveness of interventions 
designed to increase screening.
The study found that obstetrician- 
gynecologists did not perform a
chlamydia test at 82% of visits 
with pelvic examinations and 
at 77% of visits with Pap tests. 
Primary care physicians did not 
perform a chlamydia test at 99% 
of visits with urinalyses.
A d v a n c e s  in 
L a b o r a t o r y  Tes t ing  
fo r  Sexu al l y 
T r a n s m i t t e d  
Diseases
NCHHSTP is working to 
make it easier to diagnose LGV 
(Lymphogranuloma venereum), 
a sexually transmitted disease 
caused by three strains of the 
bacterium Chlamydia trachomatis. 
NCHHSTP researchers have 
refined a real-time polymerase 
chain reaction (PCR) diagnostic 
test to differentiate LGV from 
non-LGV infection of the rectum. 
In addition, the test is able to 
detect specimens that contain 
PCR inhibitors and can verify the 
adequacy of the specimen.
LGV can be difficult to diagnose. 
Typically, the primary lesion pro­
duced by LGV is a small genital 
or rectal lesion, which can ulcerate 
at the site of transmission after an 
incubation period of 3 to 30 days. 
These ulcers may remain unde­
tected. As with other STDs that 
cause ulcers, LGV may facilitate 
transmission and acquisition of 
HIV. Although LGV infections are 
thought to be relatively rare in the 
United States, the number of U.S. 
cases is unknown. Outbreaks in 
the Netherlands and other Europe­
an countries among men who have
sex with men have raised concerns 
about possible cases of LGV in the 
United States.
Cost E f fe c t iv e n e s s  
of  C h la m y d ia  
S c re e n in g  
an d H u m an 
P a p i l l o m a v i r u s  
P r e v e n t io n
NCHHSTP has conducted cost- 
effectiveness research for chlamyd­
ia testing and HPV prevention. 
One study analyzed the cost- 
effectiveness of screening high-risk 
men for chlamydia against the 
alternative of expanding chlamydia 
screening of lower-risk women. 
Screening high-risk men was 
found to be cost-saving compared 
to expanding screening in lower­
risk women. Screening high-risk 
men also resulted in treatment of 
a greater proportion of chlamydial 
infections and prevention of more 
sequelae of infection at lower over­
all cost. The chlamydia prevalence 
in men was 86% higher than the 
prevalence in women who would
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have been screened as an alterna­
tive. This suggests that limited 
programs targeting venues that 
have access to high-risk men can 
be a valuable tool in chlamydia 
prevention.
Another NCHHSTP study used 
a simplified model, based on the 
current economic and health 
effects of HPV, to estimate the 
cost-effectiveness of HPV vaccina­
tion of 12-year-old girls in the 
United States. HPV vaccination 
of 12-year-old girls was found 
to be cost-effective by the usual 
standards of cost-effectiveness in 
the United States. Results were 
consistent with previous studies 
based on more complex models. 
This consistency is important be­
cause models of various degrees of 
complexity will be essential tools 
for policy makers in the develop­
ment of optimal HPV vaccination 
strategies.
D ia g n o s in g  
H e p a t i t i s  C
NCHHSTP has developed a 
novel approach to viral hepatitis 
diagnostics. Members of its bioin­
formatics laboratory constructed 
a computational model based on 
an artificial neural network that is 
able to predict the structure of vi­
ral proteins from genetic informa­
tion alone, paving the way toward 
rationally designed diagnostic as­
says. As reported recently in Bioin­
formatics, this unique model was 
applied to enhance dramatically 
the ability to detect antibodies to 
hepatitis C virus.
I d e n t i f y i n g  
P a t t e r n s  in t h e  
H e p a t i t i s  C 
Virus  G e n o m e  
T h a t  S h ap e  t h e  
E v o lu t io n  of  
H e p a t i t i s  C
Like HIV, the hepatitis C virus 
mutates continually during virus 
replication, which helps it become 
resistant to drug therapy. NCHH- 
STP scientists have identified 
molecular interaction patterns in 
the HCV genome that shape the 
evolution of HCV, thus providing 
a basis for developing strategies 
to devise new antiviral drugs and 
forestall vaccine escape or drug re­
sistance mutations. This research, 
published in the journal Proceed­
ings o f the National Academy o f Sci­
ence o f the United States o f America, 
(July 15, 2008;28:9685-90) was 
done at CDC using computer 
modeling to explore the effect of 
mutations in each of the 3,010 
codon sites of genotype 1b HCV. 
The scientists found that muta­
tions in only 60 sites increased 
the virus’s ability to replicate; 
mutations in 1,905 sites decreased 
replication and in other sites had 
no effect. Importantly, mutations 
were linked— or “coordinated”— 
with each other, with some link­
ages stronger than others. Thus the 
likelihood and effect of mutations 
could be analyzed as a complex 
network, identifying sites at which 
mutations would have the most 
impact on viral replication and 
thus be more suitable targets for 
drugs and vaccines.
C lu ster  of  H e p a t i t i s  
C Virus  In f e c t io n s  
A ss oc ia ted  W i th  
a S u b u r b a n  H igh  
School
The absence of a laboratory test 
that distinguishes acute from 
chronic hepatitis C virus infection 
has impeded prevention and con­
trol efforts by making it difficult 
to assess national HCV infection 
incidence and identify clusters of 
recent transmission that may be 
targeted for intervention. Using 
funds provided by NCHHSTP for 
enhanced hepatitis surveillance, 
the New York State Department 
of Health and the Erie County 
Department of Health investi­
gated reports of HCV infection 
in persons under age 30, used as a 
surrogate for possible recent infec­
tion, and identified a cluster of 20 
recently-infected persons who had 
attended a single high school in 
suburban Buffalo.
Nearly all persons reported injec­
tion drug use. This discovery led 
to several prevention and control 
initiatives by state and county 
health authorities, in collabora­
tion with school districts and local 
healthcare providers, to promote 
prevention education and services 
in areas with high HCV infection 
rates. These included prevention of 
injection drug use and bloodborne 
pathogen transmission and provi­
sion of primary care, STD/HIV 
screening, drug treatment, harm 
reduction, hepatitis testing, and 
treatment services.
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The results, reported in M M W R  
(May 16, 2008;57(19):517-21), 
demonstrate the potential for 
improved hepatitis C surveillance 
to identify cases, estimate the 
magnitude of HCV infection and 
disease, detect outbreaks, evaluate 
response measures, and develop ef­
fective prevention measures. Given 
limited resources, an enhanced 
surveillance approach that gives 
highest priority to likely new cases 
of HCV infection, such as those 
in persons aged <30 years, can be 
implemented to identify clusters 
and outbreaks.
I m p o r t a n c e  
of  D e l i v e r y  
H o sp i ta ls  in 
I m p l e m e n t i n g  t h  e 
N a t i o n a l  S t r a t e g y  
to  El im in a te  
H e p a t i t i s  B V irus  
Transm iss io n  in t h e  
U n i t e d  States
Administration of the first dose 
of hepatitis B vaccine shortly af­
ter birth is important to prevent 
transmission from mothers with 
chronic HBV infection to their 
infants. Vaccination is important 
because infants who are infected 
perinatally have a high likelihood 
of remaining chronically infected 
and developing cirrhosis or liver 
cancer as adults. The Advisory 
Committee on Immunization 
Practices recommends that all 
pregnant women be screened for 
hepatitis B and that newborns of 
chronically infected women receive 
post-exposure prophylaxis within
12 hours after birth. However, 
implementation of this recom­
mendation is incomplete.
NCHHSTP, in collaboration with 
the National Center for Immuni­
zation and Respiratory Diseases, 
analyzed data from the 2006 
National Immunization Survey 
and found that during January 
2003-June 2005, the national 
newborn hepatitis B vaccina­
tion coverage estimate was only 
42.8% at age 1 day and 50.1% 
at age 3 days, with substantial 
variation across states and local 
areas (MMWR  July 24, 2008; 
57(30):825-8.). These data reveal 
that newborn hepatitis B vac­
cination coverage is low and that 
delivery hospitals play a key role in 
the national strategy to eliminate 
hepatitis B transmission by ensur­
ing vaccination of all newborns 
before discharge.
H e a l t h y  People  
in a H ea l t hy  
Wor ld
A n t i r e t r o v i r a l  
T r e a t m e n t  C ost ing  
S tu d y
CDC is contributing to PEPFAR 
support of antiretroviral treat­
ment (ART) to over 1.73 million 
individuals throughout the world. 
Efficient scale-up of ART requires 
an accurate estimation of resource 
needs and an understanding of 
how these needs change over time 
as a result of changes in the epi­
demic.
CDC is providing leadership on 
an ART costing/budgeting study 
in five countries: Nigeria, Uganda, 
Ethiopia, Botswana, and Vietnam. 
The 45-site study is designed to
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estimate the cost of providing 
comprehensive HIV treatment 
in PEPFAR-supported programs. 
Preliminary analysis of the two- 
year, multi-country study indicates 
that treatment costs vary widely 
across facilities and that the com­
position of spending changes 
markedly as programs mature.
This study generated interest 
among other PEPFAR-funded 
countries, prompting three ad­
ditional countries to conduct eco­
nomic evaluations of HIV treat­
ment using country-level funding. 
The lessons learned from this proj­
ect will be incorporated into an 
economic evaluation curriculum 
currently under development.
H IV  C o u n s e l in g  
and  Tes t ing  in TB 
p r o g r a m s
TB is the leading cause of death 
among HIV-infected individuals, 
and one of the most common op­
portunistic infections. The preva­
lence of HIV infection among 
patients in TB clinical settings is 
high— up to 80% in some coun­
tries. In many countries, GAP has
worked with partners to support 
the expansion of provider-initiated 
testing and counseling among TB 
patients and collaborated with 
international partners to develop 
and disseminate protocols, train­
ing, and policy to improve the 
integration of HIV and TB service 
care.
CDC developed a new tool to 
assist countries in planning and 
implementing provider-initiated 
counseling and testing in TB clini­
cal settings. The tool includes a 
template for national guidance for 
provider-initiated HIV testing and 
counseling programs and proce­
dures, a training curriculum for 
clinic staff, and provider job aids.
The tool was field tested with the 
assistance of the National AIDS 
Control Program and the National 
Tuberculosis and Leprosy Program 
of Tanzania. In preliminary evalua­
tions 3 months after training, 88% 
of TB patients in the clinical sites 
where the program was imple­
mented had accepted and under­
gone HIV testing. Health care 
providers in these TB clinical set­
tings remained highly motivated, 
retained skills in pre- and post-test 
counseling and record keeping
that they obtained 
through train­
ing on voluntary 
counseling and 
testing, and often 
requested that 
expanded HIV 
care and treatment 
activities, such as 
ART, be provided 
in their programs.
A p p l i c a t i o n  of  a 
B ro a d ly  S en s i t ive  
G e n o t y p i n g  Assay  
for  S u r v e i l l a n c e  
of  HIV-1 D rug  
R es is tan ce  in 
PEPFAR C o u n t r ie s
GAP, through PEPFAR, is leading 
efforts to provide HIV drug resis­
tance surveillance in resource-lim­
ited settings. These critical surveil­
lance data help guide public health 
policies to reduce occurrences of 
drug resistance and inform the 
selection of future drug regimens, 
without draining resources from 
higher-priority treatment, preven­
tion, and laboratory expansion 
activities.
An important part of GAP’s criti­
cal support has been the develop­
ment of a broadly sensitive assay 
that uses dried blood spots to de­
tect resistance, even when plasma 
viral load is low (<400 copies/ml). 
GAP applied this assay to dried 
blood spots samples collected 
from HIV-infected individuals 
(who had never had treatment) 
from China, Malawi, and Tanza­
nia. With the dried blood spots 
samples collected under field con­
ditions, GAP was able to genotype 
90% of the samples. This assay is 
less expensive and broadly sensi­
tive, and it will be an essential tool 
in the implementation of HIV 
drug resistance surveillance and 
monitoring in resource-limited 
countries. The data were presented 
at the XVII International HIV 
Drug Resistance Workshop.
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H e a l t h y  People  
in H e a l t h y  Places
L a t e n t  T u be rc u lo s is  
I n f e c t i o n  
T r e a t m e n t  in t h e  
U n i t e d  Sta tes  and  
C a n a d a
The second phase of a three-part 
study evaluated acceptance and 
completion of treatment for latent 
TB infection in the United States 
and Canada using retrospective 
chart reviews and clinic surveys 
at 68 clinics. O f persons offered 
treatment, 83% accepted it, with 
employees of a health care facility 
more likely and contacts of a pa­
tient with TB less likely to decline. 
A 9-month course of isoniazid 
was prescribed for 1,674 persons 
(84.0%), 6 months of isoniazid 
for 181 persons (9.1%), and 4 
months of rifampin for 91 persons 
(4.6%). Overall, less than half 
(47%) of 1,994 persons initiating 
treatment for latent TB infection 
completed therapy. Risk factors 
for failure to complete included 
initiating the 9-month regimen, 
residence in a congregate setting, 
injection drug use, age >15 years, 
and employment at a health care 
facility. Shorter regimens and in­
terventions targeting residents of 
congregate settings, injection drug 
users and employees of health care 
facilities are needed to increase 
completion rates.
P r e v a le n c e  of  
T u be rc u lo s is  
I n f e c t i o n  in t h e  
U n i t e d  Sta tes
This study used National Health 
and Nutrition Examination 
Survey data from 1999-2000 to 
determine the prevalence of TB 
infection in the United States. 
Prevalence in the United States 
was estimated to be 4.2%, or 
over 11 million persons. TB 
infection was especially preva­
lent among the foreign-born 
(18.7%), non-Hispanic blacks/ 
African-Americans (7.0%), 
Mexican-Americans (9.4 %), 
and individuals living in poverty 
(6.1%). The study found that 
while progress in controlling TB 
has been made, a large number of 
the U.S. population is still infected 
with TB and therefore at risk of 
developing TB disease. This study 
provides a strong scientific founda­
tion for understanding the risk 
of TB among those born abroad, 
African Americans, and the poor.
D e v e l o p m e n t  
and  E v a lu a t io n  
of  a T ubercu lo s is  
Vacc ine
Over one third of the world’s 
population is infected with My­
cobacterium tuberculosis. The 
current vaccine, based on the at­
tenuated strain M. bovis BCG and 
administered intradermally, has 
variable efficacy among different 
populations. NCHHSTP research 
has identified a possible subunit
vaccine that induces a strong anti- 
mycobacterial response when ad­
ministered via intranasal route in 
a mouse model. These results have 
led to the filing of an international 
patent for the development of a 
new mucosal subunit vaccine to 
prevent TB. NCHHSTP research­
ers and colleagues at CDC and 
Emory Vaccine Center have been 
awarded a $100,000 grant from 
the Georgia Research Alliance to 
evaluate the protective efficacy and 
mechanisms of protection of this 
new subunit vaccine.
E p i d e m i o l o g y  of  
TB A m o n g  F o r e i g n -  
b o r n  Persons in t h e  
U n i te d  Sta tes
NCHHSTP analyzed data from 
the National Tuberculosis Surveil­
lance System and the U.S. Census 
Bureau to study the Epidemiology 
of TB among foreign-born persons 
in the United States. The study 
found that rates of TB disease have
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declined among both U.S.-born 
persons and foreign-born persons, 
but that rate of decline has been 
much slower for foreign-born 
persons, thereby widening the 
disparity in TB case rates between 
the two. In 2006, 57% of all TB 
cases in the United States occurred 
among foreign-born persons.
The study estimated that adding 
TB culture testing to overseas 
pre-immigration screening for 
U.S.-bound migrants would have 
prevented the importation of at 
most 250 TB cases per year from 
2001-2006. Since approximately 
7,000 TB cases occur among 
foreign-born persons each year, 
additional strategies are needed. 
Finding and treating latent TB 
infection is one such strategy, but 
with over 37 million foreign-born 
persons living in the United States, 
reaching out to all of them would 
not be feasible.
The study found that the risk of 
TB among foreign-born persons 
varies based on time since U.S. 
entry, age at U.S. entry, and 
country of birth. Annual TB case 
rates declined with increasing time 
since U.S. entry, but rates never 
decline to the level of U.S.-born 
persons. Case rates were highest 
for persons born in most countries 
of sub-Saharan Africa and South­
east Asia, exceeding 100 times the 
rate of U.S.-born persons during 
the first 2 years after U.S. arrival. 
Over half of all cases ofTB in 
foreign-born persons occur in 
the 20% of foreign-born persons 
born in the highest risk countries, 
which include most countries of 
sub-Saharan Africa and South and
Southeast Asia. The study was 




Publ ica t ion  of  
Guide l ines
U p d a t e d
R e c o m m e n d a t i o n s  
for  H ep a t i t is  B 
S c re e n in g  and  
E v a lu a t io n  and  
M a n a g e m e n t  
of  C h ro n ica  l l y 
I n f e c t e d  Persons  
and  T h e i r  C onta c ts
Serologic testing for hepatitis B 
surface antigen (HBsAg) is the 
primary method for identifying 
persons with chronic hepatitis 
B virus infection. NCHHSTP 
published updated and expanded 
CDC guidelines for HBsAg test­
ing, including new recommenda­
tions for public health evaluation 
and management for chronically 
infected persons and their con­
tacts (M M W R , September 2008). 
Testing has been recommended 
previously for pregnant women, 
infants born to HBsAg-positive 
mothers, household contacts and 
sex partners of hepatitis B-infected 
persons, persons born in countries 
with HBsAg prevalence of >8%, 
persons who are the source of 
blood or body fluid exposures that 
might warrant post-exposure pro­
phylaxis (e.g., needle-stick injury 
to a healthcare worker or sexual 
assault), and persons infected with 
HIV.
The new recommendations, which 
were developed with input from 
a two-day consultants meeting, 
include routine testing for HBsAg 
in additional populations with 
HBsAg prevalence of >2%: per­
sons born in geographic regions 
with HBsAg prevalence of >2%, 
men who have sex with men, and 
injection-drug users. The recom­
mendations report is intended 
to serve as a resource for public 
health officials, organizations, and 
health-care professionals involved 
in the development, delivery, and 
evaluation of prevention and clini­
cal services.









NCHHSTP  B U DG E T
Budget
N CHHSTP receives fund­ing from the Labor-HHS appropriation to sup­
port both its domestic and global 
programs. Most funding comes 
through the HIV/AIDS, Viral 
Hepatitis, STD and TB prevention 
budget activity, and the Global 
Health budget activity. In addi­
tion, NCHHSTP’s Global AIDS 
Program receives significant sup­
port from the Global HIV/AIDS 
Initiative (GHAI) account. Other 
critical sources of support include 
the budget activities for CDC 
Leadership and Management, 
Emerging Infections, Food Safety 
(for hepatitis A), Health Market­
ing, and Health Informatics.
Funding for most domestic 
programs has remained level or 
declined slightly over the past 4 
years. (See figure 1.) In 2007, ad­
ditional funding of $45 million 
was directed to the President’s do­
mestic HIV Testing Initiative.
O f NCHHSTP’s $1 billion do­
mestic budget, the majority of 
funds, nearly 70%, goes to domes­
tic HIV prevention programs, with 
the rest distributed to TB, STD 
and viral hepatitis prevention pro­
grams. (See figure 2.) The major­
ity of the overall domestic budget 
funds, about 86%, was distributed 
extramurally to state and local 
health departments, nongovern­
mental agencies, universities and 
other partners. (See figure 3.)
Funding from the GHAI account 
for global activities of the Global 
AIDS Program has increased 
significantly to support the
President’s Emergency Plan for 
AIDS Relief. (See figure 4.)
Other budget lines at CDC sup­
port the Center’s health commu­
nications activities, health infor­
matics activities, and leadership 
and management. Also, Emerging 
Infectious Disease (EID) funds
support surveillance for vaccine 
preventable STDs (Hepatitis B 
and HPV), and surveillance for 
drug resistant infections (e.g. 
gonorrhea). In addition, some of 
NCHHSTP’s activities to prevent 
hepatitis A are supported through 
the Food Safety Budget activity. 
(See table 1.)
*HIV amounts in FYs 2007 and 2008 reflect President's Initiative for HIV testing.
**The budget for FY2008 level by a Continuing Appropriations Act that expires March 6, 2009.
36 N a t i o n a l  C e n t e r  f o r  H I V / A I D S ,  V i r a l  H e p a t i t i s ,  S T D ,  a n d  T B  P r e v e n t i o n
NCHHSTP  B UDGE T
*2007 amounts for food safety and emerging infectious diseases reflect the addition of the Division of Viral Hepatitis to the Center in 
2007. EID funding also supports activities related to anti-m icrobial resistant STDs, and m onitoring related to vaccine-preventable dis­
eases.
**In 2007, funding for health marketing was reduced to reflect the transfer o f funds for the National Prevention Information Network 
(formerly known as the AIDS Clearinghouse) back to the HIV prevention budget line.

















P E R F O R M A N C E  I NDI CATORS
NCHHSTP’s domestic and international portfolios have been reviewed by the Office of Management and 
Budget (OMB) and found to be performing effectively. Results are available at www.expectmore.gov. In col­
laboration with OMB, the Center has established 45 performance indicators to assess the extent to which our 
efforts result in real changes in health outcomes in the United States and abroad. These indicators reveal that 
positive progress is being made; data on 58% of the indicators have improved just since 2002. NCHHSTP is 
working to improve outcomes in those areas where progress has not been made and to establish data systems to 
assess performance in other areas.
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Pe r fo r m a n c e  Measures for  HIV/AIDS,  Vi ral  Hep at i t i s ,  
STD, and TB Pr ev ent ion
D o m e s t ic  H IV /A ID S  P r e v e n t io n
GOAL 1: DECREASE THE ANNUAL HIV INCIDENCE RATE 1
MEASURE BASELINE RESULT
1. Decrease the annual HIV incidence. 56,300 (2006) Not Available
2. Decrease the number of pediatric AIDS cases. 118 68 (2005)
3. Reduce the black:white rate ratio of HIV/AIDS diagnoses.* 10.33:1 8.71:1 (2005)
4. Reduce the Hispanic:white rate ratio of HIV/AIDS diagnoses.* 4.1:1 3.5:1 (2005)
5. Increase the number of states with mature, name-based HIV 
surveillance systems. 29 34
6. Increase the percentage of HIV prevention program grantees 
using Program Evaluation and Monitoring System (PEMS) to 
monitor program implementation.
0 (2006) Not Available
7. Increase the number of evidence-based prevention interven­
tions that are packaged and available for use in the field by 
prevention program grantees.
7 16
8. Increase the number of agencies trained each year to imple­
ment Diffusion of Effective Behavior Interventions (DEBIs). 53 1147
Data Source: Measure 1 - HIV/AIDS Incidence Surveillance in 34 states. Measures 2 - 5 - HIV/AIDS Reporting System (eHARS). 
Measure 6 - Program Evaluation and M on ito ring  System (PEMS). Measure 7 - Replicating Effective Programs (REP) Project data. 
Measure 8 - D iffusion o f Effective Behavioral In terventions (DEBI) Tracking Database.
* Data for these measures is derived from 33 states w ith mature, stable HIV case surveillance. These states are: Alabama, Alaska, 
Arizona, Arkansas, Colorado, Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, 
Nevada, New Jersey, New York, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, 
Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming.
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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GOAL 2: DECREASE THE RATE OF HIV TRANSMISSION BY HIV-INFECTED PERSONS
MEASURE BASELINE RESULT
1. Decrease the rate of HIV transmission by HIV-infected 
persons.
Not Available Not Available
2. Decrease risky sexual and drug using behaviors among 
persons at risk for transmitting HIV.
Not Available Not Available
Data Source: Measure 1 - Calculations of HIV incidence and prevalence, utilizing HIV/AIDS Incidence 
Surveillance System and special prevalence studies; Measure 2 - Medical Monitoring Project (MMP).
GOAL 3: DECREASE RISKY SEXUAL AND DRUG USING BEHAVIORS AMONG 
PERSONS AT RISK FOR ACQUIRING HIV
MEASURE BASELINE RESULT
1. Decrease risky sexual and drug-using behaviors among 
persons at risk for acquiring HIV. MSM -  47% (2004) Not Available
2. Increase the proportion of persons at risk for HIV who 
received HIV prevention interventions. MSM -  18.9% (2004) Not Available
Data Source: Measures 1 and 2 -  National HIV Behavior Surveillance (NHBS) System.
V J
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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GOAL 4: INCREASE THE PROPORTION OF HIV-INFECTED PEOPLE IN THE U.S. 
WHO KNOW THEY ARE INFECTED
MEASURE BASELINE RESULT
1. Increase the proportion of HIV-infected people in the 
United States who know they are infected. 74.5% (2003) 79% (2006)
2. Increase the proportion of persons with HIV-positive test 
results from publicly funded counseling and testing sites 
who receive their test results.
81% 83% (2006)
3. Increase the proportion of people with HIV diagnosed 
before progression to AIDS.* 78.1% 79.7% (2006)
Data Source: Measure 1 -  Special studies using eHARS. Measure 2 - Counseling, Testing, and Referral System 
CTR) g Program Evaluation and Monitoring System (PEMS). Measure 3 - eHARS.
* Data for these measures is derived from 33 states with mature, stable HIV case surveillance. These states are: Alabama, Alaska, Arizona, Arkansas, 
Colorado, Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York, New 
Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and 
Wyoming.
GOAL 5: INCREASE THE PROPORTION OF HIV-INFECTED PERSONS WHO ARE 
LINKED TO PREVENTION AND CARE SERVICES
MEASURE BASELINE RESULT
1. Increase the percentage of HIV-infected persons in publicly 
funded counseling and testing sites who were referred to 
Prevention Counseling and Referral Services (PCRS).
Not Available Not Available
2. Increase the percentage of HIV-infected persons in publicly 
funded counseling and testing sites who were referred to 
medical care and attended their first appointment.
Not Available Not Available
3. Increase the percentage of HIV-infected persons in publicly 
funded counseling and testing sites who were referred to 
HIV prevention services.
Not Available Not Available
4. Increase the percentage of HIV-infected persons in medical 
care who initiated medical care within three months of 
diagnosis.
Not Available Not Available
Data Source: Measures 1 - 3 -  Program Evaluation and Monitoring System (PEMS). Measure 4 - Medical 
Monitoring Project (MMP).
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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A
GOAL 6: REDUCE THE RATES OF VIRAL HEPATITIS IN THE UNITED STATES
RESULTMEASURE BASELINE
1. Reduce the rate of new cases of hepatitis A 
(per 100,000 population). 11.3/100,000 (1997)
2. Reduce the rate of new cases of hepatitis B 
(per 100,000 population). 2.6/100,000 (2003)
3. Increase the proportion of individuals knowing their 
hepatitis C virus infection status. 50% (2004)
4. Increase the number of areas reporting chronic hepatitis C 







Data Source: Measures 1, 2, 4 -  The National Notifiable Diseases Surveillance System (NNDSS); 
Measure 3 -- The National Health and Nutrition Examination Survey (NHANES).
_______________________________________________________________________________________
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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STD P r e v e n t io n
Æ TGOAL 7: REDUCE THE RATES OF NON-HIV SEXUALLY TRANSMITTED DISEASES (STDS) 
IN THE UNITED STATES
MEASURE BASELINE RESULT
1. Reduce pelvic inflammatory disease in the U.S. 197,000 146,000
2. Reduce the prevalence of chlamydia among high-risk 
women under age 25. 10.1% 13.2%
3. Reduce the prevalence of chlamydia among women 
under age 25, in publicly funded family planning clinics. 5.6% 6.9%
4. Reduce the incidence of gonorrhea in women aged 
15 to 44 (per 100,000 population). 279/100,000 290/100,000
5. Eliminate syphilis in the U.S. 2.4/100,000 3.8/100,000
6.a) Reduce the incidence of P&S syphilis in men 
(per 100,000 population). *
5.7/100,000
(2006) 6.6/100,000
6.b) Reduce the incidence of P&S syphilis in women 
(per 100,000 population). 1.1/100,000 1.1/100,000
7. Reduce the incidence of congenital syphilis 
(per 100,000 live births). 10.2/100,000 10.5/100,000
8. Reduce the racial disparity of P&S syphilis 
(reported ratio is black:white). 8.1:1 7:1
Data Source: Measure 1 -  The National Disease and Therapeutic Index (NDTI) (IMS Health). Measure 2 -­
The U.S. Department of Labor, National Job Training Program; CDC, IPP Chlamydia Prevalence Monitoring 
Project. Measure 3 -- CDC, IPP Chlamydia Prevalence Monitoring Project. Measures 4 - 8 -  STD Morbidity 
Surveillance System, CDC.  J
* In FY 2002, the incidence of P&S syphilis in men was 3.8 per 100,000 (initial 2002 baseline). However, because an 
outbreak of syphilis among men who have sex with men that occurred after 2002 has driven up the male syphilis 
rates, CDC is reporting a new baseline for 2006.
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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TB P r e v e n t io n
^  GOAL 8: DECREASE THE RATE OF CASES OF TUBERCULOSIS AMONG
U.S.-BORN PERSONS IN THE UNITED STATES
MEASURE BASELINE RESULT
1. Decrease the rate of cases of TB among U.S.-born persons 
(per 100,000 population). 2.9 2.1
2. Increase the percentage of TB patients who complete a 
course of curative TB treatment within 12 months of initiation 
of treatment (some patients require more than 12 months).
80.9% 82.7% (2005)
3. Increase the percentage of TB patients with initial positive 
cultures who also have drug susceptibility results. 93.0% 94.6%
4. Increase the percentage of infected contacts of infectious 
(Acid-Fast Bacillus (AFB) smear-positive) cases that are placed 
on treatment for latent TB infection and complete a treatment 
regimen.
41.0% 43.5% (2005)
Data Source: Measures 1 -  3 - The National TB Surveillance System. Measure 4 -The National TB 
Surveillance System and the national Aggregate Reports for TB Program Evaluation.
• Baseline established for 2002, unless otherwise indicated
• Result established from 2007 data, unless otherwise indicated
• Progress reflects performance data available as of 11/7/2008
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G lo b a l  AIDS P r o g ra m  (GAP)
GOAL 9: THE GLOBAL AIDS PROGRAM WILL HELP IMPLEMENT THE PRESIDENT'S EMERGENCY 
PLAN FOR AIDS RELIEF IN 15 FOCUS COUNTRIES BY PARTNERING WITH OTHER USG AGENCIES 
TO ACHIEVE THE GOALS OF TREATING 2 MILLION HIV-INFECTED PEOPLE AND CARING FOR 
10 MILLION PEOPLE INFECTED WITH OR AFFECTED BY HIV/AIDS BY 2008, AND PREVENTING
7 MILLION NEW HIV INFECTIONS BY 2010
Focus Country Performance Measures (Includes all USG activities)*
MEASURE BASELINE RESULT
1. Number of people receiving HIV/AIDS treatment. 69,911 (2003) 1,358,375
2. Number of individuals provided with general HIV-related 
palliative care/basic health care and support during the 
reporting period, including TB.
854,800 (2004) 3,901,543
3. Number of pregnant women receiving PMTCT services, 
including counseling and testing during the reporting period. 1,271,300 (2004) 4,011,797
4. Number of individuals who received counseling and testing 
during the reporting period (counseling includes the provision 
of test results to clients).
1,791,900 (2004) 10,580,699
Data Source: Country Operational Plans (COPS) database.
* Performance is reported for entire USG efforts by the OGAC. Data are through September 2007.
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/ GOAL 10: THE GLOBAL AIDS PROGRAM WILL HELP IMPLEMENT THE PRESIDENT'S EMERGENCY ^  
PLAN FOR AIDS RELIEF IN THE OTHER BILATERAL COUNTRIES BY PARTNERING WITH OTHER USG 
AGENCIES , INTERNATIONAL AND HOST COUNTRY ORGANIZATIONS TO ACHIEVE THE GOALS OF 
PREVENTING NEW HIV INFECTIONS, TREATING HIV-INFECTED PEOPLE, AND CARING FOR PEOPLE
INFECTED WITH OR AFFECTED BY HIV/AIDS
Other Bilateral Countries Performance Measures (Includes all USG activities)*
MEASURE BASELINE RESULT
1. Number of individuals receiving antiretroviral therapy at 
the end of the reporting period (includes PMTCT+ sites). 20,774 (2004) 276,965
2. Number of individuals trained to provide laboratory-related 
activities. 1,488 (2004) 3,988
3. Number of pregnant women who received HIV counseling 
and testing for PMTCT and received their test results. 145,133 (2004) 1,108,500
4. Number of individuals who received confidential counseling 
and testing during the reporting period. 773,649 (2004) 5,249,131
Data Source: GAP Planning and Reporting System and OGAC. 1
* This data was generated before the other bilateral countries received any specific guidance on monitoring and evaluation from OGAC. Hece, 
indicator values for certain programmatic activities appear low or non-existent due to lack of available existing data. Indicators include data from 
CDC, USAID, Peace Corps, and Department of Defense (DoD) and are based on each agency's existing indicators for reporting which were mapped 
into PEPFAR indicators. The reported indicators are a subset of the full set of PEPFAR indicators, i.e., only those for which Fy  2005 USG data is available. 
Data are through September 2007, with exception of measure 3, which is through March 2007.
O v e r a r c h i n g  N CHHSTP E f f ic ie n c y  M e a s u r e
EFFiGENCY MEASURE BASELINE
1. Increase the efficiency of core domestic HIV/AIDS surveillance 




Data Source: Measure I HIV/AID5 Reporting System ÎHARSÏ is used to collect state HIV and AIDS data; 
financial assistance information is drawn from administrative records and adjusted for inflation.
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